Viemed Healthcare (VMD) 10-K 4 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Feb. 28, 2020	Jun. 28, 2019
Cover page.
Entity Registrant Name	VIEMED HEALTHCARE, INC.
Entity Central Index Key	0001729149
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Small Business	true
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Public Float			$ 117,223,500
Entity Common Stock, Shares Outstanding		38,486,772

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 13,355	$ 10,413
Accounts receivable, net of allowance for doubtful accounts of $7,782 and $4,266 at December 31, 2019 and December 31, 2018, respectively	11,534	8,839
Inventory, net	1,360	2,887
Prepaid expenses and other assets	1,562	952
Total current assets	27,811	23,091
Long-term assets
Property and equipment	54,772	30,562
Other assets	13	0
Total long-term assets	54,785	30,562
TOTAL ASSETS	82,596	53,653
Current liabilities
Trade payables	4,700	5,884
Deferred revenue	3,315	2,590
Income taxes payable	86	152
Accrued liabilities	8,968	7,551
Current portion of lease liabilities	7,093	3,031
Current portion of long-term debt	1,750	0
Warrant conversion liability	0	363
Total current liabilities	25,912	19,571
Long-term liabilities
Accrued liabilities	2,317	1,117
Long-term lease liabilities	3,039	394
Long-term debt	7,629	0
Total long-term liabilities	12,985	1,511
TOTAL LIABILITIES	38,897	21,082
Commitments and Contingencies (Note 9)	0	0
SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 37,952,660 and 37,500,815 issued and outstanding as of December 31, 2019 and December 31, 2018, respectively	3,366	71
Additional paid-in capital	6,377	5,390
Accumulated other comprehensive loss	(157)	0
Retained earnings	34,113	27,110
TOTAL SHAREHOLDERS' EQUITY	43,699	32,571
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 82,596	$ 53,653

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 7,782	$ 4,266	$ 3,060
Issued (in shares)	37,952,660	37,500,815
Outstanding (in shares)	37,952,660	37,500,815

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenue	$ 80,256	$ 64,464
Cost of revenue	24,250	16,689
Gross profit	56,006	47,775
Operating Expenses
Selling, general and administrative	41,381	34,304
Research and development	848	0
Stock-based compensation	3,886	2,702
Depreciation	671	588
Loss on disposal of property and equipment	360	54
Other expense	113	71
Income from operations	8,747	10,056
Non-operating expenses
Unrealized (gain) loss on warrant conversion liability	(363)	205
Interest expense, net of interest income	314	181
Net income before taxes	8,796	9,670
Provision for income taxes	271	162
Net income	8,525	9,508
Other Comprehensive Income
Change in unrealized loss on derivative instruments, net of tax	(157)
Change in unrealized loss on derivative instruments, net of tax		0
Other Comprehensive Loss	(157)	0
Comprehensive Income	$ 8,368	$ 9,508
Net income per share
Basic (in dollars per share)	$ 0.23	$ 0.25
Diluted (in dollars per share)	$ 0.21	$ 0.24
Weighted average number of common shares outstanding:
Basic (in shares)	37,716,864	37,892,118
Diluted (in shares)	39,747,509	39,677,704

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional paid-in capital	Accumulated other comprehensive loss	Retained earnings
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2017		37,909,628
Shareholders' equity, beginning balance at Dec. 31, 2017	$ 21,951	$ 67	$ 2,688	$ 0	$ 19,196
Increase (Decrease) in Stockholders' Equity
Net Income	2,223
Shareholders' equity, ending balance at Mar. 31, 2018	24,739
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2017		37,909,628
Shareholders' equity, beginning balance at Dec. 31, 2017	21,951	$ 67	2,688	0	19,196
Increase (Decrease) in Stockholders' Equity
Stock-based compensation - options	802		802
Stock-based compensation - restricted stock	1,900		1,900
Exercise of warrants (in shares)		1,890
Exercise of warrants	4	$ 4
Shares repurchased and canceled under the Normal Course Issuer Bid (in shares)		(410,703)
Shares repurchased and canceled under the Normal Course Issuer Bid	(1,594)				(1,594)
Net Income	$ 9,508				9,508
Shareholders' equity, ending balance (in shares) at Dec. 31, 2018	37,500,815	37,500,815
Shareholders' equity, ending balance at Dec. 31, 2018	$ 32,571	$ 71	5,390	0	27,110
Shareholders' equity, beginning balance at Mar. 31, 2018	24,739
Increase (Decrease) in Stockholders' Equity
Net Income	2,098
Shareholders' equity, ending balance at Jun. 30, 2018	27,498
Increase (Decrease) in Stockholders' Equity
Net Income	2,219
Shareholders' equity, ending balance at Sep. 30, 2018	30,392
Increase (Decrease) in Stockholders' Equity
Net Income	$ 2,968
Shareholders' equity, ending balance (in shares) at Dec. 31, 2018	37,500,815	37,500,815
Shareholders' equity, ending balance at Dec. 31, 2018	$ 32,571	$ 71	5,390	0	27,110
Increase (Decrease) in Stockholders' Equity
Net Income	1,958
Shareholders' equity, ending balance at Mar. 31, 2019	$ 33,891
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2018	37,500,815	37,500,815
Shareholders' equity, beginning balance at Dec. 31, 2018	$ 32,571	$ 71	5,390	0	27,110
Increase (Decrease) in Stockholders' Equity
Stock-based compensation - options	2,642		2,642
Stock-based compensation - restricted stock	$ 1,244		1,244
Exercise of warrants (in shares)	133,000	133,170
Exercise of warrants	$ 260	$ 260	0
Exercise of options (in shares)	42,000	42,168
Exercise of options	$ 136	$ 136
Shares issued for vesting of restricted stock units (in shares)		641,607
Shares issued for vesting of restricted stock units	0	$ 2,899	(2,899)
Change in unrealized loss on derivative instruments	(157)			(157)
Shares repurchased and canceled under the Normal Course Issuer Bid (in shares)		(365,100)
Shares repurchased and canceled under the Normal Course Issuer Bid	(1,522)				(1,522)
Net Income	$ 8,525				8,525
Shareholders' equity, ending balance (in shares) at Dec. 31, 2019	37,952,660	37,952,660
Shareholders' equity, ending balance at Dec. 31, 2019	$ 43,699	$ 3,366	6,377	(157)	34,113
Shareholders' equity, beginning balance at Mar. 31, 2019	33,891
Increase (Decrease) in Stockholders' Equity
Net Income	1,326
Shareholders' equity, ending balance at Jun. 30, 2019	36,136
Increase (Decrease) in Stockholders' Equity
Net Income	2,853
Shareholders' equity, ending balance at Sep. 30, 2019	40,324
Increase (Decrease) in Stockholders' Equity
Net Income	$ 2,388
Shareholders' equity, ending balance (in shares) at Dec. 31, 2019	37,952,660	37,952,660
Shareholders' equity, ending balance at Dec. 31, 2019	$ 43,699	$ 3,366	$ 6,377	$ (157)	$ 34,113

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net Income	$ 8,525	$ 9,508
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation	6,400	3,783
Change in allowance for doubtful accounts	9,811	6,195
Share-based compensation	3,886	2,702
Unrealized (gain) loss on warrant conversion liability	(363)	205
Loss on disposal of property and equipment	360	54
Net change in working capital
Increase in accounts receivable	(12,506)	(5,253)
Increase in inventory	(306)	(1,254)
Increase in trade payables	783	2,498
Increase in deferred revenue	725	807
Increase in accrued liabilities	2,461	3,586
(Decrease) Increase in income tax payable	(66)	10
Increase in prepaid expenses and other current assets	(623)	(473)
Net cash provided by operating activities	19,087	22,368
Cash flows from investing activities
Purchase of property and equipment	(13,385)	(6,114)
Proceeds from sale of property and equipment	574	813
Net cash used in investing activities	(12,811)	(5,301)
Cash flows from financing activities
Proceeds from exercise of options	136	0
Proceeds from exercise of warrants	260	4
Proceeds from commercial long-term note for building	4,837	0
Proceeds from term note	5,000	0
Principal payments on notes payable	67	0
Principal payments on term note	(391)	0
Shares repurchased and canceled under the Normal Course Issuer Bid	(1,522)	(1,594)
Repayments of lease liabilities	(11,587)	(10,162)
Net cash used in financing activities	(3,334)	(11,752)
Net increase in cash and cash equivalents	2,942	5,315
Cash and cash equivalents at beginning of year	10,413	5,098
Cash and cash equivalents at end of period	13,355	10,413
Supplemental disclosures of cash flow information
Cash paid during the period for interest	333	193
Cash paid during the period for income taxes, net of refunds received	338	151
Supplemental disclosures of non-cash transactions
Property and equipment financed through finance leases	12,011	8,408
Property and equipment financed through operating leases under FASB ASC 842	$ 615	$ 0

Nature of Business and Operatio

Nature of Business and Operations	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Operations	Nature of Business and Operations On December 21, 2017, Viemed Healthcare, Inc. (the "Company") consumated Asset and Share Purchase Agreements as well as an Arrangement Agreement (the "Arrangement") with Protech Home Medical Corp. ("PHM") (formerly Patient Home Monitoring Corp.) and was spun-out as a separate public company that owns a 100% interest in Home Sleep Delivered, L.L.C. ("HSD") and Sleep Management, L.L.C. dba Viemed ("Viemed") through the U.S. holding company Viemed Inc. Effective as of the spin-out date, the consolidated financial statements include all of the above referenced entities. The spin-out transaction was treated as a common control transaction and all assets and liabilities of the spun out business were transferred at the prior carrying values. The Company, through its subsidiaries, provides in-home durable medical equipment ("DME") and health care solutions to patients in 31 states in the United States. Viemed offers customers requiring respiratory services and related equipment an appropriate selection of home medical products including non-invasive ventilators, positive airway pressure (“PAP”) machines and oxygen units, as well as the services of experienced respiratory therapists. HSD provides in-home sleep apnea testing, allowing a patient to determine the existence of sleep apnea at home at a fraction of the cost of the traditional sleep lab environment. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508. The Company qualifies as a "foreign private issuer," as defined in Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), for the purposes of the informational requirements of the Exchange Act. Although, as a foreign private issuer, the Company would not be required to do so, the Company will file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the SEC, instead of filing the reporting forms available to foreign private issuers. The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act"), and as such, has elected to comply with certain reduced U.S. public company reporting requirements. The Company’s common shares are traded in Canada on the Toronto Stock Exchange (the "TSX") under the symbol VMD.TO, and as of August 9, 2019, in the U.S. on the Nasdaq Capital Market under the symbol VMD.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of the SEC. In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows have been made. We have classified $3.6 million of rental equipment purchased but not provided to patients as property and equipment as of December 31, 2019 . As of December 31, 2018 , this rental equipment purchased but not provided to patients was $1.8 million and classified as inventory. These reclassifications had no effect on the reported results of operations. Reporting Currency All values are in U.S. dollars ($ or "USD") unless specifically indicated otherwise. Canadian dollars are indicated as CAD$. Functional Currency Management has exercised judgment in selecting the functional currency of each of the entities that it consolidates based on the primary economic environment in which the entity operates and in reference to the various indicators including the currency that primarily influences or determines the selling prices of goods and services and the cost of those services, including labor, material and other costs and the currency whose competitive forces and regulations mainly determine selling prices. The Company's functional currency was determined to be the U.S. dollar, which was determined using management’s assumption that the primary economic environment which it will derive its revenue and expenses incurred to generate those revenues is the United States. Basis of Consolidation These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. Reclassification of Balances Certain reclassifications have been made to current-year revenue presentation as part of the adoption of FASB Accounting Standards Codification Topic 842, “Leases,” ("Topic 842") as further discussed below within Recently Adopted Accounting Pronouncements. These reclassifications include the reporting of bad debt expense net within the revenue line item on the Consolidated Statement of Income and Comprehensive Income for the year ended December 31, 2019 . Bad debt expense is reported within selling, general and administrative expense for the year ended December 31, 2018 , consistent with FASB Accounting Standards Codification “Leases” Topic 840, which was superseded by Topic 842. These reclassifications have no effect on the reported net income for the years ended December 31, 2019 and 2018 . Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and temporary investments with an original maturity of three months or less that are readily convertible to known amounts of cash that are subject to insignificant risk or change. At December 31, 2019 and 2018 , our cash was held primarily in checking and money market accounts. Cash and cash equivalents consist of the following at December 31, 2019 and 2018 : December 31, 2019 December 31, 2018 Cash $ 3,974 $ 4,021 Money market accounts 9,381 6,392 Total cash and cash equivalents $ 13,355 $ 10,413 Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows. The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts. The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows: December 31, 2019 December 31, 2018 Balance, beginning of year $ 4,266 $ 3,060 Change in allowance for doubtful accounts 9,811 6,195 Amounts written off (6,295 ) (4,989 ) Balance, end of period $ 7,782 $ 4,266 As of December 31, 2019 and 2018 , no one customer represented more than 10% of outstanding accounts receivable. The Company has receivables at December 31, 2019 from Medicare and Medicaid, representing 45% and 13% , respectively, and 58% combined, of total outstanding receivables ( December 31, 2018 - 60% ). As these receivables are both from government programs, there is very little credit risk associated with these balances. Revenues from Medicare and Medicaid accounted for 64% and 70% , of the total revenues for the year ended December 31, 2019 and 2018 , respectively. Inventory Inventory consists primarily of respiratory supplies, non-serialized. We have classified $3.6 million of rental equipment purchased but not provided to patients as property and equipment as of December 31, 2019 . As of December 31, 2018 , this rental equipment purchased but not provided to patients was $1.8 million and classified as inventory. Non-serialized inventory represents spare equipment parts, consumables, and associated product supplies. Non-serialized inventory is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. The inventory value is determined using the first-in first-out method. Obsolete and unserviceable inventories are valued at estimated net realizable value. Property and Equipment Property and equipment is presented on the consolidated balances sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property, leasehold improvements, and equipment are amortized on a straight-line basis over their estimated useful lives. The estimated useful lives of the property and equipment are as follows: Description Estimated Useful Lives Medical Equipment 2 - 10 Years Computer Equipment 5 Years Office Furniture & Fixtures 5 - 10 Years Leasehold Improvements Shorter of Useful Life or Lease Vehicles 5 Years Building 15 - 39 Years Land Indefinite Life Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been deployed to a patient’s address and is put in use and continues through the useful life of the asset. Property and equipment and other non-current assets with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Comprehensive Income Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments. Accumulated other comprehensive loss is presented in the accompanying balance sheets as a component of shareholders' equity. Revenue Recognition Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursements by government-sponsored healthcare programs and insurance companies for such services. The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare & Medicaid Services (“CMS”). For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare. The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized straight line, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with the Financial Accounting Standards Board ("FASB") ASC 842 and 840, “Leases,” (Topic 842 and 840). For any DME sales and services, the Company recognizes revenue under FASB Accounting Standards Update ("ASU") 2014-09, “Revenue from Contracts with Customers,” (Topic 606) and related amendments. The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month , less estimated adjustments, in accordance with ASC 842 and 840, "Leases." The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company considers the lease classification (sales-type lease or operating lease) and then appropriately recognizes rental revenue over the lease term. The revenues from each major source are summarized in the following table: For the Year Ended December 31, 2019 December 31, 2018 (1) Net revenue from rentals under Topic 842 and 840 (2) Ventilator rentals, non-invasive and invasive $ 69,067 $ 57,919 Other durable medical equipment rentals 5,379 2,738 Net revenue from sales and services under Topic 606 Equipment sales 4,395 2,824 Service revenues 1,415 983 Total net revenue $ 80,256 $ 64,464 (1) Net revenue from rentals and total net revenue have been updated to reflect the correction described in Note 3 to the Notes to Consolidated Financial Statements. (2) Net revenue from rentals for the years ended December 31, 2019 and 2018 are presented under Topic 842 and 840, respectively. Revenue Accounting under Topic 842 and 840 The Company leases DME such as non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company considers these rentals to be operating leases. Under FASB Accounting Standards Codification Topic 842, “Leases”, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid. Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. The Company classified bad debt expense within selling, general and administrative expense for the year ended December 31, 2018 , consistent with FASB Accounting Standards Codification “Leases” Topic 840, which was superseded by Topic 842. After adoption of Topic 842, as previously discussed within Reclassification of Balances, the Company classified bad debt expense net within the revenue line item on the Consolidated Statement of Income and Comprehensive Income for the year ended December 31, 2019 . These amounts are reclassified in the unaudited summarized quarterly financial information included in Note 13. Revenue Accounting under Topic 606 The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. The Company also provides sleep study services to customers and recognizes revenue when the results of the sleep study are complete as that is when the performance obligation is met. The transaction price on both equipment sales and sleep studies is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the durable medical equipment business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered. The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer. Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. Returns and refunds are not accepted on either equipment sales or sleep study services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of December 31, 2019 . Stock-Based Compensation The Company accounts for its stock-based compensation in accordance with ASC 718—Compensation—Stock Compensation, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. For the Company’s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service. Income Taxes The Company is subject to income taxes in numerous jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company’s income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company’s effective tax rate as well as its business and operations. Income tax expense consists of current and deferred tax expense. Current and deferred tax are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or other comprehensive income. Current tax is recognized and measured at the amount expected to be recovered from or payable to the taxation authorities based on the income tax rates enacted at the end of the reporting period and includes any adjustment to taxes payable in respect of previous years. Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the consolidated balance sheets and a charge to or recovery of income tax expense. Deferred tax is recognized on any temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable earnings. The effect of a change in the enacted tax rates is recognized in net earnings and comprehensive income or in equity depending on the item to which the adjustment relates. Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are evaluated for recoverability based on whether it is more likely than not that sufficient taxable earnings will be available to allow all or part of the asset to be recovered. Impairment of Long-Lived Assets The Company follows ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the asset group’s carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell. There were no impairment charges recognized during the periods ended December 31, 2019 and 2018 . Net Income per Share Attributable to Common Stockholders The Company uses the two-class method to compute net income per common share attributable to common stockholders because the Company issued securities, other than common stock, that contractually entitled the holders to participate in the dividends and earnings prior to the initial listing after the Arrangement. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Under the two-class method, for periods with net income, basic net income per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of the current period's earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. See Note 11 for earnings per share computations. Recently Adopted Accounting Pronouncements In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) - Classification of Certain Cash Receipts and Cash Payments,” to provide clarity on how certain cash receipt and cash payment transactions are presented and classified within the statement of cash flows. The ASU is effective for annual periods beginning December 31, 2018, and its adoption did not impact our consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-07 “Improvements to Non-employee Share-Based Payment Accounting,” which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. The ASU is effective for interim periods as of January 1, 2019, and its adoption did not have any material impact on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842) (“ASC 842”), which supersedes the existing guidance for lease accounting, “Leases” (Topic 840) (“ASC 840”). ASC 842 requires lessees to recognize a lease liability and a right of use asset for all leases that extend beyond one year. This standard was adopted using the modified retrospective transition approach at the adoption date of January 1, 2019. This approach does not require the restatement of previous periods. The Company completed a qualitative and quantitative assessment of its leases from both a lessee and lessor perspective. As part of this process, the Company elected to utilize certain practical expedients that provided transition relief. Accordingly, the Company did not reassess expired or existing contracts, lease classifications or related initial direct costs as part of the assessment process for either lessee or lessor leases. From a lessor perspective, the Company recognizes revenue on rentals in accordance with Topic 842 on a straight line basis over the term of the lease. The adoption of this standard, from a lessee perspective, resulted in the recording of Right of Use (“ROU”) operating lease assets as a component of property and equipment, net and liabilities as a component of current and non-current liabilities of approximately $1.5 million on the Consolidated Balance Sheet as of January 1, 2019, with no impact to retained earnings. In addition, the Company elected as an accounting policy, not to record leases with an initial term of less than 12 months. (See Note 6 – “Debt and lease liabilities” for additional information and required disclosures.) Adoption of this standard had no change on finance leases previously subject to capital lease treatment under Topic 840. In August 2017, the FASB issued ASU No. 2017-12, "Derivatives and Hedging", which changes both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results, in order to better align an entity’s risk management activities and financial reporting for hedging relationships. The amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The Company adopted this standard on June 1, 2019 and adoption of this standard did not have a material impact on the Company’s consolidated financial statement presentation or results. Recently Issued Accounting Pronouncements The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, (the “Securities Act”), for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses,” to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The ASU will be effective for interim and annual periods beginning January 1, 2020 for issuers and annual periods beginning January 1, 2023 for non-issuers. The Company anticipates adopting this ASU on January 1, 2023 given its smaller reporting company status and is still evaluating the impact of adoption on the consolidated financial statements in future periods. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance modifies the disclosure requirements on fair value measurements. The ASU is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. While the Company continues to evaluate the effect of adopting this guidance, the Company expects the fair value disclosures related to financial instruments, derivative instruments and hedging activities and earnout liabilities will be subject to the new standard. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the effect of the new guidance.

Correction of Prior Period Imma

Correction of Prior Period Immaterial Errors	12 Months Ended
	Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Correction of Prior Period Immaterial Errors	Correction of Prior Period Immaterial Errors The Company has identified immaterial errors in the Company’s previously issued Consolidated Financial Statements related to revenue recognition. The Company previously recorded full monthly rental revenue for its durable medical equipment in the month of billing instead of on a daily, pro-rata basis over the lease term, consistent with the straight-line methodology required by ASC 840 and ASC 842. As a result, the Company has made certain corrections to defer revenue for rental days that extend outside of the reporting period, as well as the associated direct incremental cost of the lease. In evaluating whether the previously issued Consolidated Financial Statements were materially misstated for the interim or annual periods prior to December 31, 2019 , the Company applied the guidance of ASC 250, Accounting Changes and Error Corrections, SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Assessing Materiality and SAB Topic 1.N, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements and concluded that the effect of the errors on prior period annual financial statements was immaterial; however, the cumulative effect of correcting all of the prior period misstatements in the current year would be material to the current year consolidated financial statements. The guidance states that prior-year misstatements which, if corrected in the current year would materially misstate the current year’s financial statements, must be corrected by adjusting prior year financial statements, even though such correction previously was and continues to be immaterial to the prior-year financial statements. Correcting prior-year financial statements for such immaterial misstatements does not require previously filed reports to be amended. The cumulative effect of adjustments required to correct the misstatements in the financial statements for years prior to 2019 are reflected in the 2018 financial statements. The cumulative effect of those adjustments on all periods prior to 2018 decreased retained earnings as of December 31, 2017 by $1.8 million . The Consolidated Balance Sheet and Statements of Income, Changes in Shareholders' Equity, and Cash Flows have been adjusted to reflect the correction for the year ended December 31, 2018 . The Company’s consolidated financial statements have been revised from the amounts previously reported to correct these errors as shown in the tables below. We also revised our financial statements for each of the interim periods in the years ended December 31, 2019 and 2018 . See Note 13. Consolidated Balance Sheet as of December 31, 2018 : As Previously Reported Corrections As Adjusted Prepaid expenses and other assets $ 824 $ 128 $ 952 Total current assets 22,963 128 23,091 Total assets 53,525 128 53,653 Deferred revenue — 2,590 2,590 Total current liabilities 16,981 2,590 19,571 Total liabilities 18,492 2,590 21,082 Retained earnings 29,572 (2,462 ) 27,110 Total shareholders' equity 35,033 (2,462 ) 32,571 Total liabilities and shareholders' equity 53,525 128 53,653 Consolidated Statement of Income for the year ended December 31, 2018 : As Previously Reported Corrections As Adjusted Revenue $ 65,271 $ (807 ) $ 64,464 Gross profit 48,582 (807 ) 47,775 Selling, general, and administrative 34,442 (138 ) 34,304 Income from operations 10,725 (669 ) 10,056 Net income before taxes 10,339 (669 ) 9,670 Net income and comprehensive income 10,177 (669 ) 9,508 Net income per share: Basic $ 0.27 $ (0.02 ) $ 0.25 Diluted $ 0.26 $ (0.02 ) $ 0.24 Consolidated Statement of Cash Flows for the year ended December 31, 2018 : As Previously Reported Corrections As Adjusted Cash flows from operating activities: Net income $ 10,177 $ (669 ) $ 9,508 Increase in deferred revenue — 807 807 (Increase) other current assets (335 ) (138 ) (473 )

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment The Company’s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment. In May 2019, the Company purchased a 77,000 square foot commercial building located in Lafayette, Louisiana to utilize as its corporate headquarters. The Building Term Note used to finance this purchase is further discussed in Note 6. The following table details the Company’s fixed assets: December 31, 2019 December 31, 2018 Medical equipment $ 56,202 $ 35,541 Furniture and equipment 2,350 1,174 Land 2,138 367 Buildings 6,351 264 Leasehold improvements 301 256 Vehicles 1,110 1,782 Less: Accumulated depreciation (13,680 ) (8,822 ) Property and equipment, net of accumulated depreciation $ 54,772 $ 30,562 Depreciation in the amount of $5,729,000 and $3,195,000 is included in the cost of revenue for the years ended December 31, 2019 and 2018 , respectively. Included in medical equipment above is equipment acquired under finance lease obligations whose cost and accumulated depreciation at December 31, 2019 total $15,680,000 and $1,337,000 , respectively. At December 31, 2018 , cost and accumulated depreciation on equipment acquired under capital lease obligations was $7,943,000 and $1,100,000 , respectively. Medical equipment purchases with a cost of $2,817,000 and $4,785,000 was included in accounts payable at December 31, 2019 and 2018 , respectively.

Current Liabilities

Current Liabilities	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Current Liabilities	Current Liabilities The Company’s short-term accrued liabilities are included within current liabilities and consist of the following: December 31, 2019 December 31, 2018 Accrued trade payables $ 1,023 $ 960 Accrued commissions payable 371 315 Accrued bonuses payable 2,292 3,788 Accrued vacation and payroll 1,502 1,012 Current portion of phantom share liability 3,129 1,476 Accrued other liabilities 651 — Total accrued liabilities $ 8,968 $ 7,551

Debt and lease liabilities

Debt and lease liabilities	12 Months Ended
	Dec. 31, 2019
Debt And Leases [Abstract]
Debt and lease liabilities	Debt and Lease Liabilities Senior Credit Facility On February 20, 2018, the Company entered into a two year commercial business loan agreement with Hancock Whitney Bank. Any amounts advanced will be secured by substantially all assets and carry an interest rate of one month ICE libor plus 3.00% , with a 4.00% interest rate floor. Advances on the line of credit initially were subject to a borrowing base as determined in accordance with the loan agreement, which was based on the value of the Company's accounts receivable balance. On March 19, 2019, the Company entered into an amendment to the loan agreement increasing the available line of credit from $5.0 million to $10.0 million and extending the expiration date to March 19, 2021. In addition, the borrowing base restriction was removed from the loan agreement. On September 19, 2019, in conjunction with the Term Note described below, the Company entered into a third amendment to the loan agreement, which, among other things, replaced the financial covenants in the loan agreement with the following: Financial Covenant Required Ratio Ratio as of December 31, 2019 Total Debt to Adjusted EBITDA (Quarterly) not more than 1.50:1.00 1.03 Fixed Charge Coverage Ratio (Quarterly) not less than 1.35:1.00 4.41 Loan-to-Value Ratio (Quarterly) not more than 0.85 0.72 The Company was in compliance with all covenants in effect at December 31, 2019 . There were no borrowings against this line of credit at December 31, 2019 and December 31, 2018 . Commercial Term Notes On May 30, 2019, the Company entered into a second amendment to the loan agreement providing for a term note (the “Building Term Note”) in favor of Hancock Whitney Bank in the principal amount of $4,845,000 . The proceeds of the Building Term Note were used to purchase a building to utilize as a corporate headquarters. Beginning July 1, 2019, the Company began making monthly payments towards the outstanding balance. The Building Term Note matures on May 30, 2026 and is secured by substantially all of the assets of the borrowers, including the real property acquired with the proceeds of the Building Term Note. The Building Term Note bears interest at a variable rate equal to the one month ICE libor index plus a margin of 2.45% per annum. The Company is required to maintain a loan to value ratio of 85% with respect to the appraised value of the real property. In connection with the Building Term Note, the Company entered into an interest rate swap transaction (the "Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68% . The Company incurred immaterial financing costs related to the real property acquired with the proceeds of the Building Term Note. These deferred financing costs are amortized over the term of the loan using the effective interest method. On September 19, 2019, the Company entered into a third amendment to the loan agreement providing for a term note (the “Term Note") in favor of Hancock Whitney Bank in the principal amount of $5,000,000 . The proceeds of the Term Note will be used for general corporate purposes. Beginning October 19, 2019, the Company started making monthly principal payments of $139,000 towards the outstanding balance. The Term Note matures on September 19, 2022 and is secured by substantially all of the assets of the borrowers. The Term Note bears interest at the rate of 4.60% per annum. The Company has recognized these term notes, which have terms greater than twelve months, as follows: December 31, 2019 December 31, 2018 Notes payable $ 9,379 $ — Less: Current portion of notes payable (1,750 ) — Net long-term notes payable $ 7,629 $ — The table below represents the future minimum principal and interest obligations for the term notes as of December 31, 2019 : Principal Payments Interest Payments (1) 2020 $ 1,750 $ 400 2021 1,837 319 2022 1,475 235 2023 167 201 2024 176 194 Thereafter 3,974 273 Total $ 9,379 $ 1,622 (1) Interest payments under the term notes have effective interest rates of 4.68% and 4.60% per annum. Leases The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows: December 31, 2019 December 31, 2018 Lease liabilities $ 10,132 $ 3,425 Less: Current portion of lease liabilities (7,093 ) (3,031 ) Net long-term lease liabilities $ 3,039 $ 394 Finance lease liabilities The Company has various finance leases for equipment with an implied interest rate at fixed rates of up to 10.98% , secured by equipment, due between 2020 and 2022. The Company's weighted average interest rate was 2.48% and 1.78% for all finance lease liabilities outstanding as of December 31, 2019 and 2018 , respectively. At December 31, 2019 and 2018 , the weighted average lease term was approximately 1.07 years and 0.88 years . Minimum payments and interest for finance lease obligations required over the next five years as of December 31, 2019 , are as follows: Principal Payments Interest Payments 2020 $ 6,538 $ 155 2021 1,804 35 2022 11 — Total $ 8,353 $ 190 Interest expense related to these finance lease obligations for the year ended December 31, 2019 amounted to $147,000 . Interest expense related to these finance lease obligations for the year ended December 31, 2018 amounted to $181,000 . Operating lease liabilities The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. These leases contain renewal options that we have not included as part of the Company's assessment of the lease term as it is not reasonably certain that the Company will exercise these options. These lease liabilities are recorded at present value based on a discount rate of 5.50% , which was based on the Company's incremental borrowing rate at the time of assessment. At December 31, 2019 , the weighted average lease term was approximately 4.05 years . Minimum payments and interest for operating lease liabilities required over the next five years as of December 31, 2019 , are as follows: Principal Payments Interest Payments 2020 $ 555 $ 72 2021 472 51 2022 212 36 2023 224 24 2024 227 12 Thereafter 89 1 Total $ 1,779 $ 196 Operating rental expenses were $408,000 for the year ended December 31, 2019 and $404,000 for the year ended December 31, 2018 . Included within these operating lease liabilities are real property leases for real estate from a related party. On August 1, 2015, the Company entered a ten -year triple net lease agreement for office space with a rental company that is affiliated with the Company’s CEO, Casey Hoyt, and President, Michael Moore. Rental payments under these related party lease agreements are $20,000 per month, plus taxes, utilities and maintenance. Total rental payments for the use of these properties were $242,000 for the year ended December 31, 2019 and $235,000 for the year ended December 31, 2018 . The expense for these related party rents has been included within selling, general and administrative expenses.

Fair value measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value measurement	Fair Value Measurement Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active. Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. The Company’s cash and cash equivalents are measured using Level 1 inputs and include cash on hand, deposits in banks, certificates of deposit and money market funds. Due to their short-term nature, the carrying amounts reported in the consolidated balance sheets approximate the fair value of cash and cash equivalents. The fair value of debt is classified as Level 2 for the periods presented and approximates its carrying value. Warrants Pursuant to the Arrangement with PHM effective December 21, 2017, PHM common share purchase warrant holders each received one tenth (1/10) of one warrant to purchase one common share of the Company. The warrants conversion feature is denominated in Canadian dollars which is different from the functional currency of the Company, which is U.S. dollars. The conversion feature is treated as a derivative financial liability and the fair value movement during the period is recognized in the Consolidated Statement of Income and Comprehensive Income. The change in the value of warrants has been recorded as an unrealized (gain) loss on derivative financial liability in the Consolidated Statements of Income and Comprehensive Income. All unexercised warrants expired during the period ended December 31, 2019 . The warrant derivative financial liability was valued using Level 3 inputs from the fair value hierarchy. There were 133,000 warrants exercised at a weighted average price of $2.60 (CAD$) per common share and 44,000 warrants that expired during the year ended December 31, 2019 . No warrants were issued during the year ended December 31, 2018 . A summary of the change in fair value of warrant conversion liability is as follows for the period ended December 31, 2019 and December 31, 2018 : Warrant Conversion Liability Balance December 31, 2017 $ 158 Warrants issued — Loss on warrant conversion liability 205 Balance December 31, 2018 $ 363 Warrants issued — Unrealized gain on warrant conversion liability (363) Balance December 31, 2019 $ — Derivative instruments and hedging activities We currently have one interest rate swap contract in place, which became effective on May 31, 2019 and has been designated as a cash flow hedge. This swap contract matures on May 30, 2026. This swap contract converts the variable interest rate to a fixed interest rate on borrowings under the Building Term Note. As of December 31, 2019 , the notional amount of the interest rate swap was $4.8 million and will be amortized over the term of the swap. The fair value was $0.2 million (determined based on Level 2 inputs) and is included in Accrued liabilities, as a component of Long-term liabilities as of December 31, 2019 . During 2019 , losses recognized as a result of ineffectiveness were immaterial.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Shareholders' Equity	Shareholders' Equity Authorized share capital The Company’s authorized share capital consists of an unlimited number of common shares, with no stated par value . Issued and outstanding share capital The Company has only one class of stock outstanding, common shares. As of December 31, 2019 and 2018 , 37,952,660 and 37,500,815 shares were issued and outstanding, respectively. On November 26, 2018, the Company announced that the TSX had accepted the Company’s notice of intention to make a Normal Course Issuer Bid (the “NCIB”) for its common shares in compliance with the requirements of the TSX. As of November 29, 2018, the Company was able to commence making purchases of up to a maximum of 1,875,575 common shares, which represented approximately 5% of the Company’s issued and outstanding common shares at the time. The NCIB covered the period from November 29, 2018 to November 28, 2019. For the year ended December 31, 2019 , the Company re-purchased and canceled 365,100 common shares at a cost of $1,522,000 pursuant to the NCIB that went into effect on November 29, 2018. Total shares repurchased under the NCIB were 775,803 as of December 31, 2019 . The Company’s retained earnings were reduced by the amount paid for the shares repurchased for cancellation. Warrants All outstanding warrants expired unexercised on August 27, 2019 . The following table summarizes warrant activity during the years ended December 31, 2019 and 2018 : Number of warrants (000's) Weighted average exercise price (CAD$) Balance December 31, 2017 2,601 $ 9.74 Exercised (2 ) 2.60 Expired (2,422 ) 10.27 Balance December 31, 2018 177 $ 2.60 Issued — — Exercised (133 ) 2.60 Expired (44 ) 2.60 Balance December 31, 2019 — $ — No warrants were issued, 133,000 warrants were exercised at a weighted price of $2.60 (CAD$) per share, and 44,000 warrants expired during the year ended December 31, 2019 . Stock-based compensation At the Company's annual and special meeting of shareholders held on July 17, 2018, shareholders of the Company passed a resolution approving the RSU and Option Plans (collectively, the “Plan”). The purpose of the Plan is to provide incentives to employees, directors, officers, management companies, and consultants who provide services to the Company or any of its subsidiaries. The Plan is a “fixed” stock plan, whereby the maximum number of the Company's shares reserved for issuance, combined with any equity securities granted under all other compensation arrangements adopted by the Company, may not exceed 7,582,000 shares (equal to 20% of the issued and outstanding shares of the Company as of the date of the Arrangement). As of December 31, 2019 , the Company had outstanding issuances of options of 2,683,000 and restricted stock units of 1,139,000 under the Plan. The following table summarizes stock-based compensation for the years ended December 31, 2019 and 2018 : For the Years Ended December 31, 2019 December 31, 2018 Stock-based compensation - options $ 2,642 $ 802 Stock-based compensation - restricted stock 1,244 1,900 Total $ 3,886 $ 2,702 At December 31, 2019 , there was approximately $1,947,000 of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized over a weighted-average period of 2.05 years . As of December 31, 2019 , there was approximately $657,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 0.55 years . Options The following table summarizes stock option activity for the years ended December 31, 2019 and 2018 : Number of options (000's) Weighted average exercise price (CAD$) Weighted average remaining contractual life Aggregate Intrinsic Value (1) Balance December 31, 2017 878 $ 4.31 2.3 years $ 65 Issued 696 2.27 Expired / Forfeited (29 ) 4.43 Balance December 31, 2018 1,545 $ 3.39 5.8 years $ 1,605 Issued 1,269 5.77 Exercised (42 ) 4.30 Expired / Forfeited (89 ) 7.54 Balance December 31, 2019 2,683 $ 4.36 6.7 years $ 7,790 (1) The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period. The aggregate intrinsic value of options outstanding was $7,790,000 and options exercisable were $3,431,000 at December 31, 2019 . There were 42,168 options exercised during the fiscal year ended December 31, 2019 . There were no options exercised during the fiscal year ended December 31, 2018 . At December 31, 2019 , the Company had 1,037,000 exercisable stock options outstanding with a weighted average exercise price of CAD $3.83 and a weighted average remaining contractual life of 3.5 years . At December 31, 2018 , the Company had 851,000 exercisable stock options outstanding with a weighted average exercise price of CAD $4.30 and a weighted average remaining contractual life of 3.2 years . The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the proper vesting period, using the Black-Scholes option pricing model calculated using the following assumptions for issuances during the years ended December 31, 2019 and 2018 : 2019 2018 Exercise price ($CAD) $5.49 - $9.62 ($CAD) $2.18 ($CAD) Risk-free interest rate 1.59 - 1.96% 2.27 % Expected volatility 73 - 81% 138.14 % Expected life of options 10 Years 10 Years Expected dividend yield Nil Nil Fair value on date of grant ($USD) $3.40 - $5.52 ($USD) $2.27 ($USD) Restricted stock units The Company has a restricted stock unit plan ("RSU Plan"), which it uses for grants to directors, officers, and employees. The Company accounts for restricted stock units using fair value. The fair value of the restricted stock units has been charged to the consolidated statements of income and comprehensive income and credited to additional paid-in capital over the proper vesting period, based on the stock price on the date of grant. Restricted stock units vest generally over a one or three -year period. The Company accounts for forfeitures on restricted stock units under ASU 2016-09 and recognizes forfeitures in the period in which they occur. The following table summarizes restricted stock unit activity for the years ended December 31, 2019 and 2018 : Number of Restricted Stock Units (000's) Weighted average grant price (CAD$) Weighted average remaining contractual life Aggregate Intrinsic Value (1) Balance December 31, 2017 — $ — — $ — Issued 1,774 2.41 Expired / Forfeited (59 ) 2.25 Balance December 31, 2018 1,715 $ 2.41 1.01 years $ 6,575 Issued 120 6.90 Vested (641 ) 2.68 Expired / Forfeited (55 ) 2.25 Balance December 31, 2019 1,139 $ 2.74 0.55 years $ 7,129 (1) The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period. The Company issued restricted stock units to employees totaling 120,444 and 1,774,347 during the fiscal years 2019 and 2018 , respectively, with a vesting term of one to three years and fair values ranging from $1.71 ($USD) to $6.14 ($USD) per share. Phantom share units The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting. Phantom share units vest annually over a three -year period. The following table summarizes phantom share unit activity for the years ended December 31, 2019 and 2018 : Number of Phantom Share Units (000's) Balance December 31, 2017 — Issued 1,793 Expired / Forfeited (101 ) Balance December 31, 2018 1,692 Issued 351 Vested (550 ) Expired / Forfeited (143 ) Balance December 31, 2019 1,350 The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities, using a valuation method with the following inputs: December 31, 2019 December 31, 2018 Share price $ 8.13 (CAD$) $ 5.23 (CAD$) Remaining life of phantom share units 0.36 - 2.36 Years 0.5 - 3 Years Calculated fair value of phantom share units $ 5,290 $ 2,593 The total liability associated with phantom share units at December 31, 2019 is $5,290,000 , with $2,161,000 of this balance included in long-term accrued liabilities and the remaining portion of $3,129,000 in current accrued liabilities. Accrued liability and related expense is determined at each reporting period based on the stock price at period end.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Compensation Related Costs [Abstract]
Commitments and Contingencies	Commitments and Contingencies Retirement Plan The Company maintains a 401(k) retirement plan for employees to which eligible employees can contribute a percentage of their pre-tax compensation. Matching employer contributions to the 401(k) plan totaled $615,000 and $440,000 for the years ended December 31, 2019 and 2018 , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on the Company’s income tax provision and results of operations. At December 31, 2019 and 2018 , the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2016 . The Company's annual estimated effective tax rate for 2019 is 3.08% , as compared to the effective tax rate of 1.67% for the year ended December 31, 2018 . The primary component of the annual effective tax rate relates to the Company's current state income taxes, as the Company continues to generate taxable losses for U.S. federal income tax purposes. The following table reconciles income taxes calculated at combined U.S. federal and state tax rates with income tax expense in the financial statements: Year Ended December 31, 2019 December 31, 2018 (1) Net income before income taxes $ 8,796 $ 9,670 Statutory income tax rate 21.0 % 21.0 % Computed provision for income taxes 1,847 2,031 State income tax expense 632 473 Permanent differences 264 327 Deferred balance adjustments (922 ) 43 Tax rate changes — (1,161 ) Changes in valuation allowance for deferred tax assets (1,550 ) (1,551 ) Provision for income taxes $ 271 $ 162 (1) Net income before income taxes has been updated to reflect the correction described in Note 3 to the Notes to the Consolidated Financial Statements. The significant components of the provision for income taxes for the years ended December 31, 2019 and 2018 are as follows: Year Ended December 31, 2019 December 31, 2018 Current taxes: Federal $ — $ — State 271 162 Foreign — — Total current taxes 271 162 Deferred taxes — — Provision for income taxes $ 271 $ 162 Deferred Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company computes deferred tax assets and liabilities in respect of taxes that are based on taxable profit. Taxable profit is understood to be a net, rather than gross, taxable amount that gives effect to both revenues and expenses. Taxable profit will often differ from accounting profit and management may need to exercise judgment to determine whether some taxes are income taxes (subject to deferred tax accounting) or operating expenses. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply when the differences are expected to be recovered or settled. The determination of the ability of the Company to utilize tax loss carry forwards to offset deferred tax liabilities requires management to exercise judgment and make certain assumptions about the future performance of the Company. Management is required to assess whether it is “probable” that the Company will benefit from these prior losses and other deferred tax assets. Changes in economic conditions and other factors could result in revisions to the estimates of the benefits to be realized or the timing of utilizing the losses. Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset. A deferred tax asset has been recognized to the extent that the recoverability of deferred income tax assets is considered probable. The significant components of the Company’s deferred tax assets and liabilities are as follows: Year Ended December 31, 2019 December 31, 2018 Deferred tax assets: Net operating losses - US $ 2,460 $ 980 Non-capital losses - CAD — 3 Goodwill (a) 13,149 14,403 Allowance for doubtful accounts 2,016 1,105 Accrued compensation and other 595 37 Accrued phantom stock 1,370 672 Stock-based compensation 1,516 914 Deferred Revenue 858 638 Lease Liability 460 — Charitable Contributions 12 — Other 40 — UNICAP 5 19 481(a) adjustment — 10 Total deferred tax assets 22,481 18,781 Deferred tax liabilities: Right-Of-Use Asset (460 ) — Property and equipment (10,949 ) (6,196 ) Total deferred tax liabilities (11,409 ) (6,196 ) Valuation allowance: Net deferred tax asset before valuation allowance 11,072 12,585 Less: valuation allowance (11,072 ) (12,585 ) Net deferred tax asset — — (a) The Company elected to report the acquired assets at fair value at the time of the Company’s acquisition by PHM in 2015, and thus carries a goodwill asset for tax purposes subsequent to the transaction. The goodwill is amortized over 15 years for tax purposes. The Company has US loss carryforwards that expire as noted in the table below. The remaining deductible temporary differences may be carried forward indefinitely. Deferred tax assets have not been recognized in respect of these items because it is not probable that future taxable profit will be available against which the group can utilize the benefits therefrom. The Company has US loss carryforwards with the following expiry dates. A portion of these net operating losses are subject to limitation on use: Year Ended December 31, 2019 Expiring in 2034 $ 2,027 Expiring in 2037 $ 153 No expiry date $ 7,319

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year . Diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options, restricted stock units, and warrants are used to purchase common shares at the prevailing market rate. The following reflects the earnings and share data used in the basic and diluted earnings per share computations: For the Years Ended December 31, 2019 December 31, 2018 (1) Numerator - basic and diluted: Net income attributable to shareholders $ 8,525 $ 9,508 Denominator: Basic weighted-average number of common shares 37,716,864 37,892,118 Diluted weighted-average number of shares 39,747,509 39,677,704 Basic earnings per share $ 0.23 $ 0.25 Diluted earnings per share $ 0.21 $ 0.24 Denominator calculation from basic to diluted: Basic weighted-average number of common shares 37,716,864 37,892,118 Stock options and other dilutive securities 2,030,645 1,785,586 Diluted weighted-average number of shares 39,747,509 39,677,704 (1) Net income attributable to shareholders, basic earnings per share, and diluted earnings per share have been updated to reflect the correction described in Note 3 to the Notes to Consolidated Financial Statements.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Conversion of Accounts Payable into Short-term Capital Lease Subsequent to December 31, 2019 , the Company entered into a capital lease agreement with a third party and, as a result, $1,816,000 of accounts payable was converted to a short-term lease payable.

Unaudited Summarized Quarterly

Unaudited Summarized Quarterly Financial Information	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Unaudited Summarized Quarterly Financial Information	Unaudited Summarized Quarterly Financial Information The Company has prepared the quarterly statements of income data on a basis consistent with the audited financial statements. In the opinion of management, the financial information reflects all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of this data. The results of historical periods are not necessarily indicative of the results of operations for any future period. The following tables set forth our unaudited quarterly statements of income data for each of the eight quarters in the period ended December 31, 2019 (in thousands): Year Ended December 31, 2019 Dec. 31 Restated Sept. 30 (1) Restated Jun. 30 (1) Restated Mar. 31 (1) Net revenue $ 21,448 $ 20,368 $ 20,325 $ 18,115 Gross profit 14,243 14,050 14,639 13,074 Income from operations 2,658 2,160 1,638 2,291 Net income 2,388 2,853 1,326 1,958 Net income per share: Basic $ 0.06 $ 0.08 $ 0.04 $ 0.05 Diluted $ 0.06 $ 0.07 $ 0.03 $ 0.05 (1) These quarters have been updated to reflect the reclassification as described in Note 2 and the correction of errors as described in Note 3. Year Ended December 31, 2018 Dec. 31 (2) Sept. 30 (2) Jun. 30 (2) Mar. 31 (2) Net revenue $ 18,363 $ 16,930 $ 15,208 $ 13,963 Gross profit 13,519 12,829 11,023 10,404 Income from operations 2,915 2,511 2,288 2,342 Net income 2,968 2,219 2,098 2,223 Net income per share: Basic $ 0.08 $ 0.06 $ 0.05 $ 0.06 Diluted $ 0.07 $ 0.06 $ 0.05 $ 0.06 (2) These quarters have been updated to reflect the correction of immaterial errors as described in Note 3. As described in Note 3 certain corrections have been made to the Company’s previously issued Consolidated Financial Statements. The following tables present the effects of such adjustments on the Company’s unaudited summarized quarterly financial information. The effects of these adjustments were material to the Company's previously issued June 30, 2019 and September 30, 2019 quarterly financial statements and, accordingly, such periods have been restated. The tables below reflect the effect of the required adjustments on each of the quarterly periods for 2018 and the first three quarters of 2019. Also included in the 2019 tables below are the effects of the changes in the presentation of bad debt expense as the result of the adoption of ASC 842, as fully explained in Note 2. We have not included cash flow information in these tables as there is no change to total operating, investing, or financing cash flows as a result of the correction of these errors in any of the periods in the tables presented below. For the three months ended March 31, 2019 For the three months ended March 31, 2018 Previously Reported Bad Debt Presentation Corrections As Restated Previously Reported Corrections As Revised Net revenue $ 20,443 $ (2,125 ) $ (203 ) $ 18,115 $ 14,111 $ (148 ) $ 13,963 Cost of revenue 5,041 — — 5,041 3,559 — 3,559 Gross profit 15,402 (2,125 ) (203 ) 13,074 10,552 (148 ) 10,404 Operating Expenses Selling, general and administrative 11,592 (2,125 ) (7 ) 9,460 7,289 (30 ) 7,259 Research and development 234 — — 234 — — — Stock-based compensation 880 — — 880 561 — 561 Depreciation 129 — — 129 206 — 206 Loss on disposal of property and equipment 56 — — 56 36 — 36 Other expense 24 — — 24 — — — Income from operations 2,487 — (196 ) 2,291 2,460 (118 ) 2,342 Non-operating expenses Unrealized loss on warrant conversion liability 169 — — 169 72 — 72 Interest expense, net of interest income 26 — — 26 47 — 47 Net income before taxes 2,292 — (196 ) 2,096 2,341 (118 ) 2,223 Provision for income taxes 138 — — 138 — — — Net income 2,154 — (196 ) 1,958 2,341 (118 ) 2,223 Net income per share: Basic $ 0.06 $ — $ (0.01 ) $ 0.05 $ 0.06 $ — $ 0.06 Diluted $ 0.05 $ — $ — $ 0.05 $ 0.06 $ — $ 0.06 For the three months ended June 30, 2019 For the three months ended June 30, 2018 Previously Reported Bad Debt Presentation Corrections As Restated Previously Reported Corrections As Revised Net revenue $ 22,547 $ (1,733 ) $ (489 ) $ 20,325 $ 15,508 $ (300 ) $ 15,208 Cost of revenue 5,686 — — 5,686 4,185 — 4,185 Gross profit 16,861 (1,733 ) (489 ) 14,639 11,323 (300 ) 11,023 Operating Expenses Selling, general and administrative 13,244 (1,733 ) 5 11,516 7,919 (32 ) 7,887 Research and development 203 — — 203 — — — Stock-based compensation 1,034 — — 1,034 665 — 665 Depreciation 138 — — 138 124 — 124 Loss on disposal of property and equipment 85 — — 85 52 — 52 Other expense 25 — — 25 7 — 7 Income from operations 2,132 — (494 ) 1,638 2,556 (268 ) 2,288 Non-operating expenses Unrealized loss on warrant conversion liability 268 — — 268 123 — 123 Interest expense, net of interest income 20 — — 20 67 — 67 Net income before taxes 1,844 — (494 ) 1,350 2,366 (268 ) 2,098 Provision for income taxes 24 — — 24 — — — Net income 1,820 — (494 ) 1,326 2,366 (268 ) 2,098 Net income per share: Basic $ 0.05 $ — $ (0.01 ) $ 0.04 $ 0.06 $ (0.01 ) $ 0.05 Diluted $ 0.05 $ — $ (0.02 ) $ 0.03 $ 0.06 $ (0.01 ) $ 0.05 For the three months ended September 30, 2019 For the three months ended September 30, 2018 Previously Reported Bad Debt Presentation Corrections As Restated Previously Reported Corrections As Revised Net revenue $ 23,525 $ (3,078 ) $ (79 ) $ 20,368 $ 17,163 $ (233 ) $ 16,930 Cost of revenue 6,318 — — 6,318 4,101 — 4,101 Gross profit 17,207 (3,078 ) (79 ) 14,050 13,062 (233 ) 12,829 Operating Expenses Selling, general and administrative 13,281 (3,078 ) 28 10,231 9,490 (28 ) 9,462 Research and development 208 — — 208 — — — Stock-based compensation 1,064 — — 1,064 672 — 672 Depreciation 193 — — 193 128 — 128 Loss on disposal of property and equipment 167 — — 167 23 — 23 Other expense 27 — — 27 33 — 33 Income from operations 2,267 — (107 ) 2,160 2,716 (205 ) 2,511 Non-operating expenses Unrealized (gain) loss on warrant conversion liability (800 ) — — (800 ) 220 — 220 Interest expense, net of interest income 56 — — 56 37 — 37 Net income before taxes 3,011 — (107 ) 2,904 2,459 (205 ) 2,254 Provision for income taxes 51 — — 51 35 — 35 Net income 2,960 — (107 ) 2,853 2,424 (205 ) 2,219 Net income per share: Basic $ 0.08 $ — $ — $ 0.08 $ 0.06 $ — $ 0.06 Diluted $ 0.07 $ — $ — $ 0.07 $ 0.06 $ — $ 0.06 For the three months ended December 31, 2018 Previously Reported Corrections As Revised Net revenue $ 18,489 $ (126 ) $ 18,363 Cost of revenue 4,844 — 4,844 Gross profit 13,645 (126 ) 13,519 Operating Expenses Selling, general and administrative 9,744 (48 ) 9,696 Research and development — — — Stock-based compensation 804 — 804 Depreciation 130 — 130 Loss (gain) on disposal of property and equipment (57 ) — (57 ) Other expense 31 — 31 Income from operations 2,993 (78 ) 2,915 Non-operating expenses Unrealized (gain) loss on warrant conversion liability (210 ) — (210 ) Interest expense, net of interest income 30 — 30 Net income before taxes 3,173 (78 ) 3,095 Provision for income taxes 127 — 127 Net income 3,046 (78 ) 2,968 Net income per share: Basic $ 0.08 $ — $ 0.08 Diluted $ 0.08 $ (0.01 ) $ 0.07 As of As of March 31, 2018 June 30, 2018 Previously Reported Corrections As Revised Previously Reported Corrections As Revised ASSETS Current assets Cash and cash equivalents $ 4,634 $ — $ 4,634 $ 8,551 $ — $ 8,551 Accounts receivable 10,687 — 10,687 7,857 — 7,857 Inventory 1,959 — 1,959 1,935 — 1,935 Prepaid expenses and other assets 560 90 650 491 88 579 Total current assets 17,840 90 17,930 18,834 88 18,922 Long-term assets Property and equipment 22,726 — 22,726 25,334 — 25,334 Other assets — — — — — — Total long-term assets 22,726 — 22,726 25,334 — 25,334 TOTAL ASSETS $ 40,566 $ 90 $ 40,656 $ 44,168 $ 88 $ 44,256 LIABILITIES Current liabilities Trade payables $ 2,780 $ — $ 2,780 $ 3,266 $ — $ 3,266 Deferred revenue — 1,997 1,997 — 2,267 2,267 Income taxes payable 110 — 110 73 — 73 Accrued liabilities 4,246 — 4,246 4,552 — 4,552 Current portion of lease liabilities 5,247 — 5,247 4,947 — 4,947 Current portion of long-term debt — — — — — — Warrant conversion liability 230 — 230 353 — 353 Total current liabilities 12,613 1,997 14,610 13,191 2,267 15,458 Long-term liabilities Accrued liabilities — — — 252 — 252 Long-term lease liabilities 1,307 — 1,307 1,048 — 1,048 Long-term debt — — — — — — Total long-term liabilities 1,307 — 1,307 1,300 — 1,300 TOTAL LIABILITIES 13,920 1,997 15,917 14,491 2,267 16,758 SHAREHOLDERS’ EQUITY Common stock 67 — 67 67 — 67 Additional paid-in capital 3,249 — 3,249 3,914 — 3,914 Accumulated other comprehensive loss — — — — — — Retained earnings 23,330 (1,907 ) 21,423 25,696 (2,179 ) 23,517 TOTAL SHAREHOLDERS’ EQUITY 26,646 (1,907 ) 24,739 29,677 (2,179 ) 27,498 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 40,566 $ 90 $ 40,656 $ 44,168 $ 88 $ 44,256 As of As of September 30, 2018 December 31, 2018 Previously Reported Corrections As Revised Previously Reported Corrections As Revised ASSETS Current assets Cash and cash equivalents $ 10,174 $ — $ 10,174 $ 10,413 $ — $ 10,413 Accounts receivable 8,392 — 8,392 8,839 — 8,839 Inventory 2,377 — 2,377 2,887 — 2,887 Prepaid expenses and other assets 956 93 1,049 824 128 952 Total current assets 21,899 93 21,992 22,963 128 23,091 Long-term assets Property and equipment 27,248 — 27,248 30,562 — 30,562 Other assets — — — — — — Total long-term assets 27,248 — 27,248 30,562 — 30,562 TOTAL ASSETS $ 49,147 $ 93 $ 49,240 $ 53,525 $ 128 $ 53,653 LIABILITIES Current liabilities Trade payables $ 3,683 $ — $ 3,683 $ 5,884 $ — $ 5,884 Deferred revenue — 2,477 2,477 — 2,590 2,590 Income taxes payable 74 — 74 152 — 152 Accrued liabilities 5,741 — 5,741 7,551 — 7,551 Current portion of lease liabilities 4,646 — 4,646 3,031 — 3,031 Current portion of long-term debt — — — — — — Warrant conversion liability 572 — 572 363 — 363 Total current liabilities 14,716 2,477 17,193 16,981 2,590 19,571 Long-term liabilities Accrued liabilities 936 — 936 1,117 — 1,117 Long-term lease liabilities 719 — 719 394 — 394 Long-term debt — — — — — — Total long-term liabilities 1,655 — 1,655 1,511 — 1,511 TOTAL LIABILITIES 16,371 2,477 18,848 18,492 2,590 21,082 SHAREHOLDERS’ EQUITY Common stock 70 — 70 71 — 71 Additional paid-in capital 4,586 — 4,586 5,390 — 5,390 Accumulated other comprehensive loss — — — — — — Retained earnings 28,120 (2,384 ) 25,736 29,572 (2,462 ) 27,110 TOTAL SHAREHOLDERS’ EQUITY 32,776 (2,384 ) 30,392 35,033 (2,462 ) 32,571 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 49,147 $ 93 $ 49,240 $ 53,525 $ 128 $ 53,653 As of As of March 31, 2019 June 30, 2019 Previously Reported Corrections As Restated Previously Reported Corrections As Restated ASSETS Current assets Cash and cash equivalents $ 7,410 $ — $ 7,410 $ 7,691 $ — $ 7,691 Accounts receivable 11,666 — 11,666 12,797 — 12,797 Inventory 3,615 — 3,615 3,712 — 3,712 Prepaid expenses and other assets 922 135 1,057 861 128 989 Total current assets 23,613 135 23,748 25,061 128 25,189 Long-term assets Property and equipment 34,970 — 34,970 45,803 — 45,803 Other assets — — — 22 — 22 Total long-term assets 34,970 — 34,970 45,825 — 45,825 TOTAL ASSETS $ 58,583 $ 135 $ 58,718 $ 70,886 $ 128 $ 71,014 LIABILITIES Current liabilities Trade payables $ 6,388 $ — $ 6,388 $ 7,818 $ — $ 7,818 Deferred revenue — 2,793 2,793 — 3,281 3,281 Income taxes payable 148 — 148 — — — Accrued liabilities 5,850 — 5,850 6,950 — 6,950 Current portion of lease liabilities 5,966 — 5,966 8,410 — 8,410 Current portion of long-term debt — — — 133 — 133 Warrant conversion liability 532 — 532 800 — 800 Total current liabilities 18,884 2,793 21,677 24,111 3,281 27,392 Long-term liabilities Accrued liabilities 1,962 — 1,962 1,685 — 1,685 Long-term lease liabilities 1,188 — 1,188 1,098 — 1,098 Long-term debt — — — 4,703 — 4,703 Total long-term liabilities 3,150 — 3,150 7,486 — 7,486 TOTAL LIABILITIES 22,034 2,793 24,827 31,597 3,281 34,878 SHAREHOLDERS’ EQUITY Common stock 2,277 — 2,277 2,350 — 2,350 Additional paid-in capital 4,068 — 4,068 5,063 — 5,063 Accumulated other comprehensive loss — — — (148 ) — (148 ) Retained earnings 30,204 (2,658 ) 27,546 32,024 (3,153 ) 28,871 TOTAL SHAREHOLDERS’ EQUITY $ 36,549 $ (2,658 ) $ 33,891 $ 39,289 $ (3,153 ) $ 36,136 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 58,583 $ 135 $ 58,718 $ 70,886 $ 128 $ 71,014 As of September 30, 2019 Previously Reported Corrections As Restated ASSETS Current assets Cash and cash equivalents $ 12,630 $ — $ 12,630 Accounts receivable 11,729 — 11,729 Inventory 1,266 — 1,266 Prepaid expenses and other assets 2,078 100 2,178 Total current assets 27,703 100 27,803 Long-term assets Property and equipment 52,161 — 52,161 Other assets 17 — 17 Total long-term assets 52,178 — 52,178 TOTAL ASSETS $ 79,881 $ 100 $ 79,981 LIABILITIES Current liabilities Trade payables $ 4,072 $ — $ 4,072 Deferred revenue — 3,360 3,360 Income taxes payable 28 — 28 Accrued liabilities 8,600 — 8,600 Current portion of lease liabilities 8,767 — 8,767 Current portion of long-term debt 1,728 — 1,728 Warrant conversion liability — — — Total current liabilities 23,195 3,360 26,555 Long-term liabilities Accrued liabilities 2,213 — 2,213 Long-term lease liabilities 2,813 — 2,813 Long-term debt 8,076 — 8,076 Total long-term liabilities 13,102 — 13,102 TOTAL LIABILITIES 36,297 3,360 39,657 SHAREHOLDERS’ EQUITY Common stock 3,366 — 3,366 Additional paid-in capital 5,470 — 5,470 Accumulated other comprehensive loss (236 ) — (236 ) Retained earnings 34,984 (3,260 ) 31,724 TOTAL SHAREHOLDERS’ EQUITY 43,584 (3,260 ) 40,324 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 79,881 $ 100 $ 79,981

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Principles of Presentation	The accompanying financial statements have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of the SEC. In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows have been made
Functional Currency	Functional Currency Management has exercised judgment in selecting the functional currency of each of the entities that it consolidates based on the primary economic environment in which the entity operates and in reference to the various indicators including the currency that primarily influences or determines the selling prices of goods and services and the cost of those services, including labor, material and other costs and the currency whose competitive forces and regulations mainly determine selling prices. The Company's functional currency was determined to be the U.S. dollar, which was determined using management’s assumption that the primary economic environment which it will derive its revenue and expenses incurred to generate those revenues is the United States.
Basis of consolidation	Basis of Consolidation These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.
Reclassification of Balances	Reclassification of Balances Certain reclassifications have been made to current-year revenue presentation as part of the adoption of FASB Accounting Standards Codification Topic 842, “Leases,” ("Topic 842") as further discussed below within Recently Adopted Accounting Pronouncements. These reclassifications include the reporting of bad debt expense net within the revenue line item on the Consolidated Statement of Income and Comprehensive Income for the year ended December 31, 2019 . Bad debt expense is reported within selling, general and administrative expense for the year ended December 31, 2018 , consistent with FASB Accounting Standards Codification “Leases” Topic 840, which was superseded by Topic 842.
Use of estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.
Cash and cash equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and temporary investments with an original maturity of three months or less that are readily convertible to known amounts of cash that are subject to insignificant risk or change
Accounts receivable and allowance for doubtful accounts	Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows. The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.
Inventory	Inventory
Property and equipment	Property and Equipment Property and equipment is presented on the consolidated balances sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property, leasehold improvements, and equipment are amortized on a straight-line basis over their estimated useful lives. Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been deployed to a patient’s address and is put in use and continues through the useful life of the asset. Property and equipment and other non-current assets with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
Revenue recognition	Revenue Recognition Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursements by government-sponsored healthcare programs and insurance companies for such services. The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare & Medicaid Services (“CMS”). For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare. The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized straight line, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with the Financial Accounting Standards Board ("FASB") ASC 842 and 840, “Leases,” (Topic 842 and 840). For any DME sales and services, the Company recognizes revenue under FASB Accounting Standards Update ("ASU") 2014-09, “Revenue from Contracts with Customers,” (Topic 606) and related amendments. The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month , less estimated adjustments, in accordance with ASC 842 and 840, "Leases." The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company considers the lease classification (sales-type lease or operating lease) and then appropriately recognizes rental revenue over the lease term. The revenues from each major source are summarized in the following table: For the Year Ended December 31, 2019 December 31, 2018 (1) Net revenue from rentals under Topic 842 and 840 (2) Ventilator rentals, non-invasive and invasive $ 69,067 $ 57,919 Other durable medical equipment rentals 5,379 2,738 Net revenue from sales and services under Topic 606 Equipment sales 4,395 2,824 Service revenues 1,415 983 Total net revenue $ 80,256 $ 64,464 (1) Net revenue from rentals and total net revenue have been updated to reflect the correction described in Note 3 to the Notes to Consolidated Financial Statements. (2) Net revenue from rentals for the years ended December 31, 2019 and 2018 are presented under Topic 842 and 840, respectively.
Revenue Accounting under Topic 842	Revenue Accounting under Topic 842 and 840 The Company leases DME such as non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company considers these rentals to be operating leases. Under FASB Accounting Standards Codification Topic 842, “Leases”, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid. Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. The Company classified bad debt expense within selling, general and administrative expense for the year ended December 31, 2018 , consistent with FASB Accounting Standards Codification “Leases” Topic 840, which was superseded by Topic 842. After adoption of Topic 842, as previously discussed within Reclassification of Balances, the Company classified bad debt expense net within the revenue line item on the Consolidated Statement of Income and Comprehensive Income for the year ended December 31, 2019 .
Revenue Accounting under Topic 606	Revenue Accounting under Topic 606 The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. The Company also provides sleep study services to customers and recognizes revenue when the results of the sleep study are complete as that is when the performance obligation is met. The transaction price on both equipment sales and sleep studies is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the durable medical equipment business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered. The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer. Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. Returns and refunds are not accepted on either equipment sales or sleep study services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue.
Stock-based compensation	Stock-Based Compensation The Company accounts for its stock-based compensation in accordance with ASC 718—Compensation—Stock Compensation, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. For the Company’s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.
Income Taxes	Income Taxes The Company is subject to income taxes in numerous jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company’s income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company’s effective tax rate as well as its business and operations. Income tax expense consists of current and deferred tax expense. Current and deferred tax are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or other comprehensive income. Current tax is recognized and measured at the amount expected to be recovered from or payable to the taxation authorities based on the income tax rates enacted at the end of the reporting period and includes any adjustment to taxes payable in respect of previous years. Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the consolidated balance sheets and a charge to or recovery of income tax expense. Deferred tax is recognized on any temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable earnings. The effect of a change in the enacted tax rates is recognized in net earnings and comprehensive income or in equity depending on the item to which the adjustment relates. Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are evaluated for recoverability based on whether it is more likely than not that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company follows ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the asset group’s carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell.
Net Income per Share Attributable to Common Stockholders	Net Income per Share Attributable to Common Stockholders The Company uses the two-class method to compute net income per common share attributable to common stockholders because the Company issued securities, other than common stock, that contractually entitled the holders to participate in the dividends and earnings prior to the initial listing after the Arrangement. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Under the two-class method, for periods with net income, basic net income per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of the current period's earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.
Recently adopted accounting pronouncements and Recently issued accounting pronouncements	Recently Adopted Accounting Pronouncements In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) - Classification of Certain Cash Receipts and Cash Payments,” to provide clarity on how certain cash receipt and cash payment transactions are presented and classified within the statement of cash flows. The ASU is effective for annual periods beginning December 31, 2018, and its adoption did not impact our consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-07 “Improvements to Non-employee Share-Based Payment Accounting,” which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. The ASU is effective for interim periods as of January 1, 2019, and its adoption did not have any material impact on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842) (“ASC 842”), which supersedes the existing guidance for lease accounting, “Leases” (Topic 840) (“ASC 840”). ASC 842 requires lessees to recognize a lease liability and a right of use asset for all leases that extend beyond one year. This standard was adopted using the modified retrospective transition approach at the adoption date of January 1, 2019. This approach does not require the restatement of previous periods. The Company completed a qualitative and quantitative assessment of its leases from both a lessee and lessor perspective. As part of this process, the Company elected to utilize certain practical expedients that provided transition relief. Accordingly, the Company did not reassess expired or existing contracts, lease classifications or related initial direct costs as part of the assessment process for either lessee or lessor leases. From a lessor perspective, the Company recognizes revenue on rentals in accordance with Topic 842 on a straight line basis over the term of the lease. The adoption of this standard, from a lessee perspective, resulted in the recording of Right of Use (“ROU”) operating lease assets as a component of property and equipment, net and liabilities as a component of current and non-current liabilities of approximately $1.5 million on the Consolidated Balance Sheet as of January 1, 2019, with no impact to retained earnings. In addition, the Company elected as an accounting policy, not to record leases with an initial term of less than 12 months. (See Note 6 – “Debt and lease liabilities” for additional information and required disclosures.) Adoption of this standard had no change on finance leases previously subject to capital lease treatment under Topic 840. In August 2017, the FASB issued ASU No. 2017-12, "Derivatives and Hedging", which changes both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results, in order to better align an entity’s risk management activities and financial reporting for hedging relationships. The amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The Company adopted this standard on June 1, 2019 and adoption of this standard did not have a material impact on the Company’s consolidated financial statement presentation or results. Recently Issued Accounting Pronouncements The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, (the “Securities Act”), for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses,” to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The ASU will be effective for interim and annual periods beginning January 1, 2020 for issuers and annual periods beginning January 1, 2023 for non-issuers. The Company anticipates adopting this ASU on January 1, 2023 given its smaller reporting company status and is still evaluating the impact of adoption on the consolidated financial statements in future periods. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance modifies the disclosure requirements on fair value measurements. The ASU is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. While the Company continues to evaluate the effect of adopting this guidance, the Company expects the fair value disclosures related to financial instruments, derivative instruments and hedging activities and earnout liabilities will be subject to the new standard. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the effect of the new guidance.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	Cash and cash equivalents consist of the following at December 31, 2019 and 2018 : December 31, 2019 December 31, 2018 Cash $ 3,974 $ 4,021 Money market accounts 9,381 6,392 Total cash and cash equivalents $ 13,355 $ 10,413
Accounts Receivable, Allowance for Doubtful Accounts	The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows: December 31, 2019 December 31, 2018 Balance, beginning of year $ 4,266 $ 3,060 Change in allowance for doubtful accounts 9,811 6,195 Amounts written off (6,295 ) (4,989 ) Balance, end of period $ 7,782 $ 4,266
Schedule of Estimated Useful Lives	The estimated useful lives of the property and equipment are as follows: Description Estimated Useful Lives Medical Equipment 2 - 10 Years Computer Equipment 5 Years Office Furniture & Fixtures 5 - 10 Years Leasehold Improvements Shorter of Useful Life or Lease Vehicles 5 Years Building 15 - 39 Years Land Indefinite Life The following table details the Company’s fixed assets: December 31, 2019 December 31, 2018 Medical equipment $ 56,202 $ 35,541 Furniture and equipment 2,350 1,174 Land 2,138 367 Buildings 6,351 264 Leasehold improvements 301 256 Vehicles 1,110 1,782 Less: Accumulated depreciation (13,680 ) (8,822 ) Property and equipment, net of accumulated depreciation $ 54,772 $ 30,562
Schedule of Revenue by Source	The revenues from each major source are summarized in the following table: For the Year Ended December 31, 2019 December 31, 2018 (1) Net revenue from rentals under Topic 842 and 840 (2) Ventilator rentals, non-invasive and invasive $ 69,067 $ 57,919 Other durable medical equipment rentals 5,379 2,738 Net revenue from sales and services under Topic 606 Equipment sales 4,395 2,824 Service revenues 1,415 983 Total net revenue $ 80,256 $ 64,464 (1) Net revenue from rentals and total net revenue have been updated to reflect the correction described in Note 3 to the Notes to Consolidated Financial Statements. (2) Net revenue from rentals for the years ended December 31, 2019 and 2018 are presented under Topic 842 and 840, respectively.

Correction of Prior Period Im_2

Correction of Prior Period Immaterial Errors (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Schedule of Correction to Prior Period Financial Statements	Consolidated Balance Sheet as of December 31, 2018 : As Previously Reported Corrections As Adjusted Prepaid expenses and other assets $ 824 $ 128 $ 952 Total current assets 22,963 128 23,091 Total assets 53,525 128 53,653 Deferred revenue — 2,590 2,590 Total current liabilities 16,981 2,590 19,571 Total liabilities 18,492 2,590 21,082 Retained earnings 29,572 (2,462 ) 27,110 Total shareholders' equity 35,033 (2,462 ) 32,571 Total liabilities and shareholders' equity 53,525 128 53,653 Consolidated Statement of Income for the year ended December 31, 2018 : As Previously Reported Corrections As Adjusted Revenue $ 65,271 $ (807 ) $ 64,464 Gross profit 48,582 (807 ) 47,775 Selling, general, and administrative 34,442 (138 ) 34,304 Income from operations 10,725 (669 ) 10,056 Net income before taxes 10,339 (669 ) 9,670 Net income and comprehensive income 10,177 (669 ) 9,508 Net income per share: Basic $ 0.27 $ (0.02 ) $ 0.25 Diluted $ 0.26 $ (0.02 ) $ 0.24 Consolidated Statement of Cash Flows for the year ended December 31, 2018 : As Previously Reported Corrections As Adjusted Cash flows from operating activities: Net income $ 10,177 $ (669 ) $ 9,508 Increase in deferred revenue — 807 807 (Increase) other current assets (335 ) (138 ) (473 )

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The estimated useful lives of the property and equipment are as follows: Description Estimated Useful Lives Medical Equipment 2 - 10 Years Computer Equipment 5 Years Office Furniture & Fixtures 5 - 10 Years Leasehold Improvements Shorter of Useful Life or Lease Vehicles 5 Years Building 15 - 39 Years Land Indefinite Life The following table details the Company’s fixed assets: December 31, 2019 December 31, 2018 Medical equipment $ 56,202 $ 35,541 Furniture and equipment 2,350 1,174 Land 2,138 367 Buildings 6,351 264 Leasehold improvements 301 256 Vehicles 1,110 1,782 Less: Accumulated depreciation (13,680 ) (8,822 ) Property and equipment, net of accumulated depreciation $ 54,772 $ 30,562

Current Liabilities (Tables)

Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Current Liabilities	The Company’s short-term accrued liabilities are included within current liabilities and consist of the following: December 31, 2019 December 31, 2018 Accrued trade payables $ 1,023 $ 960 Accrued commissions payable 371 315 Accrued bonuses payable 2,292 3,788 Accrued vacation and payroll 1,502 1,012 Current portion of phantom share liability 3,129 1,476 Accrued other liabilities 651 — Total accrued liabilities $ 8,968 $ 7,551

Debt and lease liabilities (Tab

Debt and lease liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Debt And Leases [Abstract]
Schedule of Covenants	On September 19, 2019, in conjunction with the Term Note described below, the Company entered into a third amendment to the loan agreement, which, among other things, replaced the financial covenants in the loan agreement with the following: Financial Covenant Required Ratio Ratio as of December 31, 2019 Total Debt to Adjusted EBITDA (Quarterly) not more than 1.50:1.00 1.03 Fixed Charge Coverage Ratio (Quarterly) not less than 1.35:1.00 4.41 Loan-to-Value Ratio (Quarterly) not more than 0.85 0.72
Schedule of Notes Payable	The Company has recognized these term notes, which have terms greater than twelve months, as follows: December 31, 2019 December 31, 2018 Notes payable $ 9,379 $ — Less: Current portion of notes payable (1,750 ) — Net long-term notes payable $ 7,629 $ —
Schedule of Future Minimum Principal Obligations and Interest	The table below represents the future minimum principal and interest obligations for the term notes as of December 31, 2019 : Principal Payments Interest Payments (1) 2020 $ 1,750 $ 400 2021 1,837 319 2022 1,475 235 2023 167 201 2024 176 194 Thereafter 3,974 273 Total $ 9,379 $ 1,622 (1) Interest payments under the term notes have effective interest rates of 4.68% and 4.60% per annum.
Schedule of Lease Liabilities	The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows: December 31, 2019 December 31, 2018 Lease liabilities $ 10,132 $ 3,425 Less: Current portion of lease liabilities (7,093 ) (3,031 ) Net long-term lease liabilities $ 3,039 $ 394
Schedule of Finance Lease Liabilities	Minimum payments and interest for finance lease obligations required over the next five years as of December 31, 2019 , are as follows: Principal Payments Interest Payments 2020 $ 6,538 $ 155 2021 1,804 35 2022 11 — Total $ 8,353 $ 190
Schedule of Operating Lease Liabilities	Minimum payments and interest for operating lease liabilities required over the next five years as of December 31, 2019 , are as follows: Principal Payments Interest Payments 2020 $ 555 $ 72 2021 472 51 2022 212 36 2023 224 24 2024 227 12 Thereafter 89 1 Total $ 1,779 $ 196

Fair value measurement (Tables)

Fair value measurement (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Warrants	There were 133,000 warrants exercised at a weighted average price of $2.60 (CAD$) per common share and 44,000 warrants that expired during the year ended December 31, 2019 . No warrants were issued during the year ended December 31, 2018 . A summary of the change in fair value of warrant conversion liability is as follows for the period ended December 31, 2019 and December 31, 2018 : Warrant Conversion Liability Balance December 31, 2017 $ 158 Warrants issued — Loss on warrant conversion liability 205 Balance December 31, 2018 $ 363 Warrants issued — Unrealized gain on warrant conversion liability (363) Balance December 31, 2019 $ —

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Warrants	All outstanding warrants expired unexercised on August 27, 2019 . The following table summarizes warrant activity during the years ended December 31, 2019 and 2018 : Number of warrants (000's) Weighted average exercise price (CAD$) Balance December 31, 2017 2,601 $ 9.74 Exercised (2 ) 2.60 Expired (2,422 ) 10.27 Balance December 31, 2018 177 $ 2.60 Issued — — Exercised (133 ) 2.60 Expired (44 ) 2.60 Balance December 31, 2019 — $ —
Schedule of Stock-based Compensation Expense	The following table summarizes stock-based compensation for the years ended December 31, 2019 and 2018 : For the Years Ended December 31, 2019 December 31, 2018 Stock-based compensation - options $ 2,642 $ 802 Stock-based compensation - restricted stock 1,244 1,900 Total $ 3,886 $ 2,702
Schedule of Option Activity	The following table summarizes stock option activity for the years ended December 31, 2019 and 2018 : Number of options (000's) Weighted average exercise price (CAD$) Weighted average remaining contractual life Aggregate Intrinsic Value (1) Balance December 31, 2017 878 $ 4.31 2.3 years $ 65 Issued 696 2.27 Expired / Forfeited (29 ) 4.43 Balance December 31, 2018 1,545 $ 3.39 5.8 years $ 1,605 Issued 1,269 5.77 Exercised (42 ) 4.30 Expired / Forfeited (89 ) 7.54 Balance December 31, 2019 2,683 $ 4.36 6.7 years $ 7,790 (1) The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.
Schedule of Stock Options, Valuation Assumptions	The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the proper vesting period, using the Black-Scholes option pricing model calculated using the following assumptions for issuances during the years ended December 31, 2019 and 2018 : 2019 2018 Exercise price ($CAD) $5.49 - $9.62 ($CAD) $2.18 ($CAD) Risk-free interest rate 1.59 - 1.96% 2.27 % Expected volatility 73 - 81% 138.14 % Expected life of options 10 Years 10 Years Expected dividend yield Nil Nil Fair value on date of grant ($USD) $3.40 - $5.52 ($USD) $2.27 ($USD)
Schedule of Restricted Stock Units	The following table summarizes restricted stock unit activity for the years ended December 31, 2019 and 2018 : Number of Restricted Stock Units (000's) Weighted average grant price (CAD$) Weighted average remaining contractual life Aggregate Intrinsic Value (1) Balance December 31, 2017 — $ — — $ — Issued 1,774 2.41 Expired / Forfeited (59 ) 2.25 Balance December 31, 2018 1,715 $ 2.41 1.01 years $ 6,575 Issued 120 6.90 Vested (641 ) 2.68 Expired / Forfeited (55 ) 2.25 Balance December 31, 2019 1,139 $ 2.74 0.55 years $ 7,129 (1) The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period
Schedule of Phantom Share Units	The following table summarizes phantom share unit activity for the years ended December 31, 2019 and 2018 : Number of Phantom Share Units (000's) Balance December 31, 2017 — Issued 1,793 Expired / Forfeited (101 ) Balance December 31, 2018 1,692 Issued 351 Vested (550 ) Expired / Forfeited (143 ) Balance December 31, 2019 1,350 The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities, using a valuation method with the following inputs: December 31, 2019 December 31, 2018 Share price $ 8.13 (CAD$) $ 5.23 (CAD$) Remaining life of phantom share units 0.36 - 2.36 Years 0.5 - 3 Years Calculated fair value of phantom share units $ 5,290 $ 2,593

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The following table reconciles income taxes calculated at combined U.S. federal and state tax rates with income tax expense in the financial statements: Year Ended December 31, 2019 December 31, 2018 (1) Net income before income taxes $ 8,796 $ 9,670 Statutory income tax rate 21.0 % 21.0 % Computed provision for income taxes 1,847 2,031 State income tax expense 632 473 Permanent differences 264 327 Deferred balance adjustments (922 ) 43 Tax rate changes — (1,161 ) Changes in valuation allowance for deferred tax assets (1,550 ) (1,551 ) Provision for income taxes $ 271 $ 162 (1) Net income before income taxes has been updated to reflect the correction described in Note 3 to the Notes to the Consolidated Financial Statements.
Schedule of Components of Income Tax Expense (Benefit)	The significant components of the provision for income taxes for the years ended December 31, 2019 and 2018 are as follows: Year Ended December 31, 2019 December 31, 2018 Current taxes: Federal $ — $ — State 271 162 Foreign — — Total current taxes 271 162 Deferred taxes — — Provision for income taxes $ 271 $ 162
Schedule of Deferred Tax Assets and Liabilities	The significant components of the Company’s deferred tax assets and liabilities are as follows: Year Ended December 31, 2019 December 31, 2018 Deferred tax assets: Net operating losses - US $ 2,460 $ 980 Non-capital losses - CAD — 3 Goodwill (a) 13,149 14,403 Allowance for doubtful accounts 2,016 1,105 Accrued compensation and other 595 37 Accrued phantom stock 1,370 672 Stock-based compensation 1,516 914 Deferred Revenue 858 638 Lease Liability 460 — Charitable Contributions 12 — Other 40 — UNICAP 5 19 481(a) adjustment — 10 Total deferred tax assets 22,481 18,781 Deferred tax liabilities: Right-Of-Use Asset (460 ) — Property and equipment (10,949 ) (6,196 ) Total deferred tax liabilities (11,409 ) (6,196 ) Valuation allowance: Net deferred tax asset before valuation allowance 11,072 12,585 Less: valuation allowance (11,072 ) (12,585 ) Net deferred tax asset — — (a) The Company elected to report the acquired assets at fair value at the time of the Company’s acquisition by PHM in 2015, and thus carries a goodwill asset for tax purposes subsequent to the transaction. The goodwill is amortized over 15 years for tax purposes.
Summary of Operating Loss Carryforwards	The Company has US loss carryforwards with the following expiry dates. A portion of these net operating losses are subject to limitation on use: Year Ended December 31, 2019 Expiring in 2034 $ 2,027 Expiring in 2037 $ 153 No expiry date $ 7,319

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule of Earnings Per Share	The following reflects the earnings and share data used in the basic and diluted earnings per share computations: For the Years Ended December 31, 2019 December 31, 2018 (1) Numerator - basic and diluted: Net income attributable to shareholders $ 8,525 $ 9,508 Denominator: Basic weighted-average number of common shares 37,716,864 37,892,118 Diluted weighted-average number of shares 39,747,509 39,677,704 Basic earnings per share $ 0.23 $ 0.25 Diluted earnings per share $ 0.21 $ 0.24 Denominator calculation from basic to diluted: Basic weighted-average number of common shares 37,716,864 37,892,118 Stock options and other dilutive securities 2,030,645 1,785,586 Diluted weighted-average number of shares 39,747,509 39,677,704 (1) Net income attributable to shareholders, basic earnings per share, and diluted earnings per share have been updated to reflect the correction described in Note 3 to the Notes to Consolidated Financial Statements.

Unaudited Summarized Quarterl_2

Unaudited Summarized Quarterly Financial Information (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following tables present the effects of such adjustments on the Company’s unaudited summarized quarterly financial information. The effects of these adjustments were material to the Company's previously issued June 30, 2019 and September 30, 2019 quarterly financial statements and, accordingly, such periods have been restated. The tables below reflect the effect of the required adjustments on each of the quarterly periods for 2018 and the first three quarters of 2019. Also included in the 2019 tables below are the effects of the changes in the presentation of bad debt expense as the result of the adoption of ASC 842, as fully explained in Note 2. We have not included cash flow information in these tables as there is no change to total operating, investing, or financing cash flows as a result of the correction of these errors in any of the periods in the tables presented below. For the three months ended March 31, 2019 For the three months ended March 31, 2018 Previously Reported Bad Debt Presentation Corrections As Restated Previously Reported Corrections As Revised Net revenue $ 20,443 $ (2,125 ) $ (203 ) $ 18,115 $ 14,111 $ (148 ) $ 13,963 Cost of revenue 5,041 — — 5,041 3,559 — 3,559 Gross profit 15,402 (2,125 ) (203 ) 13,074 10,552 (148 ) 10,404 Operating Expenses Selling, general and administrative 11,592 (2,125 ) (7 ) 9,460 7,289 (30 ) 7,259 Research and development 234 — — 234 — — — Stock-based compensation 880 — — 880 561 — 561 Depreciation 129 — — 129 206 — 206 Loss on disposal of property and equipment 56 — — 56 36 — 36 Other expense 24 — — 24 — — — Income from operations 2,487 — (196 ) 2,291 2,460 (118 ) 2,342 Non-operating expenses Unrealized loss on warrant conversion liability 169 — — 169 72 — 72 Interest expense, net of interest income 26 — — 26 47 — 47 Net income before taxes 2,292 — (196 ) 2,096 2,341 (118 ) 2,223 Provision for income taxes 138 — — 138 — — — Net income 2,154 — (196 ) 1,958 2,341 (118 ) 2,223 Net income per share: Basic $ 0.06 $ — $ (0.01 ) $ 0.05 $ 0.06 $ — $ 0.06 Diluted $ 0.05 $ — $ — $ 0.05 $ 0.06 $ — $ 0.06 For the three months ended June 30, 2019 For the three months ended June 30, 2018 Previously Reported Bad Debt Presentation Corrections As Restated Previously Reported Corrections As Revised Net revenue $ 22,547 $ (1,733 ) $ (489 ) $ 20,325 $ 15,508 $ (300 ) $ 15,208 Cost of revenue 5,686 — — 5,686 4,185 — 4,185 Gross profit 16,861 (1,733 ) (489 ) 14,639 11,323 (300 ) 11,023 Operating Expenses Selling, general and administrative 13,244 (1,733 ) 5 11,516 7,919 (32 ) 7,887 Research and development 203 — — 203 — — — Stock-based compensation 1,034 — — 1,034 665 — 665 Depreciation 138 — — 138 124 — 124 Loss on disposal of property and equipment 85 — — 85 52 — 52 Other expense 25 — — 25 7 — 7 Income from operations 2,132 — (494 ) 1,638 2,556 (268 ) 2,288 Non-operating expenses Unrealized loss on warrant conversion liability 268 — — 268 123 — 123 Interest expense, net of interest income 20 — — 20 67 — 67 Net income before taxes 1,844 — (494 ) 1,350 2,366 (268 ) 2,098 Provision for income taxes 24 — — 24 — — — Net income 1,820 — (494 ) 1,326 2,366 (268 ) 2,098 Net income per share: Basic $ 0.05 $ — $ (0.01 ) $ 0.04 $ 0.06 $ (0.01 ) $ 0.05 Diluted $ 0.05 $ — $ (0.02 ) $ 0.03 $ 0.06 $ (0.01 ) $ 0.05 For the three months ended September 30, 2019 For the three months ended September 30, 2018 Previously Reported Bad Debt Presentation Corrections As Restated Previously Reported Corrections As Revised Net revenue $ 23,525 $ (3,078 ) $ (79 ) $ 20,368 $ 17,163 $ (233 ) $ 16,930 Cost of revenue 6,318 — — 6,318 4,101 — 4,101 Gross profit 17,207 (3,078 ) (79 ) 14,050 13,062 (233 ) 12,829 Operating Expenses Selling, general and administrative 13,281 (3,078 ) 28 10,231 9,490 (28 ) 9,462 Research and development 208 — — 208 — — — Stock-based compensation 1,064 — — 1,064 672 — 672 Depreciation 193 — — 193 128 — 128 Loss on disposal of property and equipment 167 — — 167 23 — 23 Other expense 27 — — 27 33 — 33 Income from operations 2,267 — (107 ) 2,160 2,716 (205 ) 2,511 Non-operating expenses Unrealized (gain) loss on warrant conversion liability (800 ) — — (800 ) 220 — 220 Interest expense, net of interest income 56 — — 56 37 — 37 Net income before taxes 3,011 — (107 ) 2,904 2,459 (205 ) 2,254 Provision for income taxes 51 — — 51 35 — 35 Net income 2,960 — (107 ) 2,853 2,424 (205 ) 2,219 Net income per share: Basic $ 0.08 $ — $ — $ 0.08 $ 0.06 $ — $ 0.06 Diluted $ 0.07 $ — $ — $ 0.07 $ 0.06 $ — $ 0.06 For the three months ended December 31, 2018 Previously Reported Corrections As Revised Net revenue $ 18,489 $ (126 ) $ 18,363 Cost of revenue 4,844 — 4,844 Gross profit 13,645 (126 ) 13,519 Operating Expenses Selling, general and administrative 9,744 (48 ) 9,696 Research and development — — — Stock-based compensation 804 — 804 Depreciation 130 — 130 Loss (gain) on disposal of property and equipment (57 ) — (57 ) Other expense 31 — 31 Income from operations 2,993 (78 ) 2,915 Non-operating expenses Unrealized (gain) loss on warrant conversion liability (210 ) — (210 ) Interest expense, net of interest income 30 — 30 Net income before taxes 3,173 (78 ) 3,095 Provision for income taxes 127 — 127 Net income 3,046 (78 ) 2,968 Net income per share: Basic $ 0.08 $ — $ 0.08 Diluted $ 0.08 $ (0.01 ) $ 0.07 As of As of March 31, 2018 June 30, 2018 Previously Reported Corrections As Revised Previously Reported Corrections As Revised ASSETS Current assets Cash and cash equivalents $ 4,634 $ — $ 4,634 $ 8,551 $ — $ 8,551 Accounts receivable 10,687 — 10,687 7,857 — 7,857 Inventory 1,959 — 1,959 1,935 — 1,935 Prepaid expenses and other assets 560 90 650 491 88 579 Total current assets 17,840 90 17,930 18,834 88 18,922 Long-term assets Property and equipment 22,726 — 22,726 25,334 — 25,334 Other assets — — — — — — Total long-term assets 22,726 — 22,726 25,334 — 25,334 TOTAL ASSETS $ 40,566 $ 90 $ 40,656 $ 44,168 $ 88 $ 44,256 LIABILITIES Current liabilities Trade payables $ 2,780 $ — $ 2,780 $ 3,266 $ — $ 3,266 Deferred revenue — 1,997 1,997 — 2,267 2,267 Income taxes payable 110 — 110 73 — 73 Accrued liabilities 4,246 — 4,246 4,552 — 4,552 Current portion of lease liabilities 5,247 — 5,247 4,947 — 4,947 Current portion of long-term debt — — — — — — Warrant conversion liability 230 — 230 353 — 353 Total current liabilities 12,613 1,997 14,610 13,191 2,267 15,458 Long-term liabilities Accrued liabilities — — — 252 — 252 Long-term lease liabilities 1,307 — 1,307 1,048 — 1,048 Long-term debt — — — — — — Total long-term liabilities 1,307 — 1,307 1,300 — 1,300 TOTAL LIABILITIES 13,920 1,997 15,917 14,491 2,267 16,758 SHAREHOLDERS’ EQUITY Common stock 67 — 67 67 — 67 Additional paid-in capital 3,249 — 3,249 3,914 — 3,914 Accumulated other comprehensive loss — — — — — — Retained earnings 23,330 (1,907 ) 21,423 25,696 (2,179 ) 23,517 TOTAL SHAREHOLDERS’ EQUITY 26,646 (1,907 ) 24,739 29,677 (2,179 ) 27,498 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 40,566 $ 90 $ 40,656 $ 44,168 $ 88 $ 44,256 As of As of September 30, 2018 December 31, 2018 Previously Reported Corrections As Revised Previously Reported Corrections As Revised ASSETS Current assets Cash and cash equivalents $ 10,174 $ — $ 10,174 $ 10,413 $ — $ 10,413 Accounts receivable 8,392 — 8,392 8,839 — 8,839 Inventory 2,377 — 2,377 2,887 — 2,887 Prepaid expenses and other assets 956 93 1,049 824 128 952 Total current assets 21,899 93 21,992 22,963 128 23,091 Long-term assets Property and equipment 27,248 — 27,248 30,562 — 30,562 Other assets — — — — — — Total long-term assets 27,248 — 27,248 30,562 — 30,562 TOTAL ASSETS $ 49,147 $ 93 $ 49,240 $ 53,525 $ 128 $ 53,653 LIABILITIES Current liabilities Trade payables $ 3,683 $ — $ 3,683 $ 5,884 $ — $ 5,884 Deferred revenue — 2,477 2,477 — 2,590 2,590 Income taxes payable 74 — 74 152 — 152 Accrued liabilities 5,741 — 5,741 7,551 — 7,551 Current portion of lease liabilities 4,646 — 4,646 3,031 — 3,031 Current portion of long-term debt — — — — — — Warrant conversion liability 572 — 572 363 — 363 Total current liabilities 14,716 2,477 17,193 16,981 2,590 19,571 Long-term liabilities Accrued liabilities 936 — 936 1,117 — 1,117 Long-term lease liabilities 719 — 719 394 — 394 Long-term debt — — — — — — Total long-term liabilities 1,655 — 1,655 1,511 — 1,511 TOTAL LIABILITIES 16,371 2,477 18,848 18,492 2,590 21,082 SHAREHOLDERS’ EQUITY Common stock 70 — 70 71 — 71 Additional paid-in capital 4,586 — 4,586 5,390 — 5,390 Accumulated other comprehensive loss — — — — — — Retained earnings 28,120 (2,384 ) 25,736 29,572 (2,462 ) 27,110 TOTAL SHAREHOLDERS’ EQUITY 32,776 (2,384 ) 30,392 35,033 (2,462 ) 32,571 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 49,147 $ 93 $ 49,240 $ 53,525 $ 128 $ 53,653 As of As of March 31, 2019 June 30, 2019 Previously Reported Corrections As Restated Previously Reported Corrections As Restated ASSETS Current assets Cash and cash equivalents $ 7,410 $ — $ 7,410 $ 7,691 $ — $ 7,691 Accounts receivable 11,666 — 11,666 12,797 — 12,797 Inventory 3,615 — 3,615 3,712 — 3,712 Prepaid expenses and other assets 922 135 1,057 861 128 989 Total current assets 23,613 135 23,748 25,061 128 25,189 Long-term assets Property and equipment 34,970 — 34,970 45,803 — 45,803 Other assets — — — 22 — 22 Total long-term assets 34,970 — 34,970 45,825 — 45,825 TOTAL ASSETS $ 58,583 $ 135 $ 58,718 $ 70,886 $ 128 $ 71,014 LIABILITIES Current liabilities Trade payables $ 6,388 $ — $ 6,388 $ 7,818 $ — $ 7,818 Deferred revenue — 2,793 2,793 — 3,281 3,281 Income taxes payable 148 — 148 — — — Accrued liabilities 5,850 — 5,850 6,950 — 6,950 Current portion of lease liabilities 5,966 — 5,966 8,410 — 8,410 Current portion of long-term debt — — — 133 — 133 Warrant conversion liability 532 — 532 800 — 800 Total current liabilities 18,884 2,793 21,677 24,111 3,281 27,392 Long-term liabilities Accrued liabilities 1,962 — 1,962 1,685 — 1,685 Long-term lease liabilities 1,188 — 1,188 1,098 — 1,098 Long-term debt — — — 4,703 — 4,703 Total long-term liabilities 3,150 — 3,150 7,486 — 7,486 TOTAL LIABILITIES 22,034 2,793 24,827 31,597 3,281 34,878 SHAREHOLDERS’ EQUITY Common stock 2,277 — 2,277 2,350 — 2,350 Additional paid-in capital 4,068 — 4,068 5,063 — 5,063 Accumulated other comprehensive loss — — — (148 ) — (148 ) Retained earnings 30,204 (2,658 ) 27,546 32,024 (3,153 ) 28,871 TOTAL SHAREHOLDERS’ EQUITY $ 36,549 $ (2,658 ) $ 33,891 $ 39,289 $ (3,153 ) $ 36,136 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 58,583 $ 135 $ 58,718 $ 70,886 $ 128 $ 71,014 As of September 30, 2019 Previously Reported Corrections As Restated ASSETS Current assets Cash and cash equivalents $ 12,630 $ — $ 12,630 Accounts receivable 11,729 — 11,729 Inventory 1,266 — 1,266 Prepaid expenses and other assets 2,078 100 2,178 Total current assets 27,703 100 27,803 Long-term assets Property and equipment 52,161 — 52,161 Other assets 17 — 17 Total long-term assets 52,178 — 52,178 TOTAL ASSETS $ 79,881 $ 100 $ 79,981 LIABILITIES Current liabilities Trade payables $ 4,072 $ — $ 4,072 Deferred revenue — 3,360 3,360 Income taxes payable 28 — 28 Accrued liabilities 8,600 — 8,600 Current portion of lease liabilities 8,767 — 8,767 Current portion of long-term debt 1,728 — 1,728 Warrant conversion liability — — — Total current liabilities 23,195 3,360 26,555 Long-term liabilities Accrued liabilities 2,213 — 2,213 Long-term lease liabilities 2,813 — 2,813 Long-term debt 8,076 — 8,076 Total long-term liabilities 13,102 — 13,102 TOTAL LIABILITIES 36,297 3,360 39,657 SHAREHOLDERS’ EQUITY Common stock 3,366 — 3,366 Additional paid-in capital 5,470 — 5,470 Accumulated other comprehensive loss (236 ) — (236 ) Retained earnings 34,984 (3,260 ) 31,724 TOTAL SHAREHOLDERS’ EQUITY 43,584 (3,260 ) 40,324 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 79,881 $ 100 $ 79,981 The following tables set forth our unaudited quarterly statements of income data for each of the eight quarters in the period ended December 31, 2019 (in thousands): Year Ended December 31, 2019 Dec. 31 Restated Sept. 30 (1) Restated Jun. 30 (1) Restated Mar. 31 (1) Net revenue $ 21,448 $ 20,368 $ 20,325 $ 18,115 Gross profit 14,243 14,050 14,639 13,074 Income from operations 2,658 2,160 1,638 2,291 Net income 2,388 2,853 1,326 1,958 Net income per share: Basic $ 0.06 $ 0.08 $ 0.04 $ 0.05 Diluted $ 0.06 $ 0.07 $ 0.03 $ 0.05 (1) These quarters have been updated to reflect the reclassification as described in Note 2 and the correction of errors as described in Note 3. Year Ended December 31, 2018 Dec. 31 (2) Sept. 30 (2) Jun. 30 (2) Mar. 31 (2) Net revenue $ 18,363 $ 16,930 $ 15,208 $ 13,963 Gross profit 13,519 12,829 11,023 10,404 Income from operations 2,915 2,511 2,288 2,342 Net income 2,968 2,219 2,098 2,223 Net income per share: Basic $ 0.08 $ 0.06 $ 0.05 $ 0.06 Diluted $ 0.07 $ 0.06 $ 0.05 $ 0.06 (2) These quarters have been updated to reflect the correction of immaterial errors as described in Note 3.

Nature of Business and Operat_2

Nature of Business and Operations (Details) - state	Dec. 31, 2019	Dec. 21, 2017
Noncontrolling Interest [Line Items]
Number of States in which entity provides DME and health care solutions	31
PHM | HSD and Viemed
Noncontrolling Interest [Line Items]
Ownership percentage		100.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Basis of Presentation and Inventory) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Property, Plant and Equipment [Line Items]
Inventory, net	$ 1,360	$ 1,266	$ 3,712	$ 3,615	$ 2,887	$ 2,377	$ 1,935	$ 1,959
Rental Equipment Purchased, But Not Provided To Patients
Property, Plant and Equipment [Line Items]
Inventory, net					$ 1,800
Rental Equipment Purchased, But Not Provided To Patients
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,600

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Cash and Cash Equivalents) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Accounting Policies [Abstract]
Cash	$ 3,974				$ 4,021
Money market accounts	9,381				6,392
Total cash and cash equivalents	$ 13,355	$ 12,630	$ 7,691	$ 7,410	$ 10,413	$ 10,174	$ 8,551	$ 4,634

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Allowance for Doubtful Accounts
Balance, beginning of year	$ 4,266	$ 3,060
Change in allowance for doubtful accounts	9,811	6,195
Amounts written off	(6,295)	(4,989)
Balance, end of period	$ 7,782	$ 4,266

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Accounts Receivable, Narrative) (Details) - Customer Concentration	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Medicare and Medicaid | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	58.00%	60.00%
Medicare and Medicaid | Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	64.00%	70.00%
Medicare | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	45.00%
Medicaid | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	13.00%

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2019
Medical equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful life	2 years
Medical equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful life	10 years
Computer Equipment
Property, Plant and Equipment [Line Items]
Useful life	5 years
Office Furniture & Fixtures | Minimum
Property, Plant and Equipment [Line Items]
Useful life	5 years
Office Furniture & Fixtures | Maximum
Property, Plant and Equipment [Line Items]
Useful life	10 years
Vehicles
Property, Plant and Equipment [Line Items]
Useful life	5 years
Building | Minimum
Property, Plant and Equipment [Line Items]
Useful life	15 years
Building | Maximum
Property, Plant and Equipment [Line Items]
Useful life	39 years

Summary of Significant Accoun_9

Summary of Significant Accounting Policies (Revenue Recognition) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue recognized period (in months)									one month
Revenue	$ 21,448	$ 20,368	$ 20,325	$ 18,115	$ 18,363	$ 16,930	$ 15,208	$ 13,963	$ 80,256	$ 64,464
Ventilator rentals, non-invasive and invasive
Disaggregation of Revenue [Line Items]
Revenue from rentals under Topic 842									69,067	57,919
Other durable medical equipment rentals
Disaggregation of Revenue [Line Items]
Revenue from rentals under Topic 842									5,379	2,738
Equipment sales
Disaggregation of Revenue [Line Items]
Revenue from sales and services under Topic 606									4,395	2,824
Service revenues
Disaggregation of Revenue [Line Items]
Revenue from sales and services under Topic 606									$ 1,415	$ 983

Summary of Significant Accou_10

Summary of Significant Accounting Policies (Impairment of Long-Lived Assets) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Impairment of long-lived assets	$ 0	$ 0

Summary of Significant Accou_11

Summary of Significant Accounting Policies (Recently Adopted Accounting Pronouncements) (Details) - ASU 2016-02 $ in Millions	Jan. 01, 2019USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease, ROU asset	$ 1.5
Operating lease, liabilities	$ 1.5

Correction of Prior Period Im_3

Correction of Prior Period Immaterial Errors (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Retained earnings	$ 34,113	$ 31,724	$ 28,871	$ 27,546	$ 27,110	$ 25,736	$ 23,517	$ 21,423
Corrections
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Retained earnings		$ (3,260)	$ (3,153)	$ (2,658)	$ (2,462)	$ (2,384)	$ (2,179)	$ (1,907)	$ (1,800)

Correction of Prior Period Im_4

Correction of Prior Period Immaterial Errors (Balance Sheet) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prepaid expenses and other assets	$ 1,562	$ 2,178	$ 989	$ 1,057	$ 952	$ 1,049	$ 579	$ 650
Total current assets	27,811	27,803	25,189	23,748	23,091	21,992	18,922	17,930
Total assets	82,596	79,981	71,014	58,718	53,653	49,240	44,256	40,656
Deferred revenue	3,315	3,360	3,281	2,793	2,590	2,477	2,267	1,997
Total current liabilities	25,912	26,555	27,392	21,677	19,571	17,193	15,458	14,610
Total liabilities	38,897	39,657	34,878	24,827	21,082	18,848	16,758	15,917
Retained earnings	34,113	31,724	28,871	27,546	27,110	25,736	23,517	21,423
Total shareholders' equity	43,699	40,324	36,136	33,891	32,571	30,392	27,498	24,739	$ 21,951
Total liabilities and shareholders' equity	$ 82,596	79,981	71,014	58,718	53,653	49,240	44,256	40,656
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prepaid expenses and other assets		2,078	861	922	824	956	491	560
Total current assets		27,703	25,061	23,613	22,963	21,899	18,834	17,840
Total assets		79,881	70,886	58,583	53,525	49,147	44,168	40,566
Deferred revenue		0	0	0	0	0	0	0
Total current liabilities		23,195	24,111	18,884	16,981	14,716	13,191	12,613
Total liabilities		36,297	31,597	22,034	18,492	16,371	14,491	13,920
Retained earnings		34,984	32,024	30,204	29,572	28,120	25,696	23,330
Total shareholders' equity		43,584	39,289	36,549	35,033	32,776	29,677	26,646
Total liabilities and shareholders' equity		79,881	70,886	58,583	53,525	49,147	44,168	40,566
Corrections
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prepaid expenses and other assets		100	128	135	128	93	88	90
Total current assets		100	128	135	128	93	88	90
Total assets		100	128	135	128	93	88	90
Deferred revenue		3,360	3,281	2,793	2,590	2,477	2,267	1,997
Total current liabilities		3,360	3,281	2,793	2,590	2,477	2,267	1,997
Total liabilities		3,360	3,281	2,793	2,590	2,477	2,267	1,997
Retained earnings		(3,260)	(3,153)	(2,658)	(2,462)	(2,384)	(2,179)	(1,907)	$ (1,800)
Total shareholders' equity		(3,260)	(3,153)	(2,658)	(2,462)	(2,384)	(2,179)	(1,907)
Total liabilities and shareholders' equity		$ 100	$ 128	$ 135	$ 128	$ 93	$ 88	$ 90

Correction of Prior Period Im_5

Correction of Prior Period Immaterial Errors (Income Statement) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	$ 21,448	$ 20,368	$ 20,325	$ 18,115	$ 18,363	$ 16,930	$ 15,208	$ 13,963	$ 80,256	$ 64,464
Gross profit	14,243	14,050	14,639	13,074	13,519	12,829	11,023	10,404	56,006	47,775
Selling, general and administrative		10,231	11,516	9,460	9,696	9,462	7,887	7,259	41,381	34,304
Income from operations	2,658	2,160	1,638	2,291	2,915	2,511	2,288	2,342	8,747	10,056
Net income before income taxes		2,904	1,350	2,096	3,095	2,254	2,098	2,223	8,796	9,670
Net Income	$ 2,388	$ 2,853	$ 1,326	$ 1,958	$ 2,968	$ 2,219	$ 2,098	$ 2,223	$ 8,525	$ 9,508
Net income per share
Basic (in dollars per share)	$ 0.06	$ 0.08	$ 0.04	$ 0.05	$ 0.08	$ 0.06	$ 0.05	$ 0.06	$ 0.23	$ 0.25
Diluted (in dollars per share)	$ 0.06	$ 0.07	$ 0.03	$ 0.05	$ 0.07	$ 0.06	$ 0.05	$ 0.06	$ 0.21	$ 0.24
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue		$ 23,525	$ 22,547	$ 20,443	$ 18,489	$ 17,163	$ 15,508	$ 14,111		$ 65,271
Gross profit		17,207	16,861	15,402	13,645	13,062	11,323	10,552		48,582
Selling, general and administrative		13,281	13,244	11,592	9,744	9,490	7,919	7,289		34,442
Income from operations		2,267	2,132	2,487	2,993	2,716	2,556	2,460		10,725
Net income before income taxes		3,011	1,844	2,292	3,173	2,459	2,366	2,341		10,339
Net Income		$ 2,960	$ 1,820	$ 2,154	$ 3,046	$ 2,424	$ 2,366	$ 2,341		$ 10,177
Net income per share
Basic (in dollars per share)		$ 0.08	$ 0.05	$ 0.06	$ 0.08	$ 0.06	$ 0.06	$ 0.06		$ 0.27
Diluted (in dollars per share)		$ 0.07	$ 0.05	$ 0.05	$ 0.08	$ 0.06	$ 0.06	$ 0.06		$ 0.26
Corrections
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue					$ (126)	$ (233)	$ (300)	$ (148)		$ (807)
Gross profit					(126)	(233)	(300)	(148)		(807)
Selling, general and administrative					(48)	(28)	(32)	(30)		(138)
Income from operations					(78)	(205)	(268)	(118)		(669)
Net income before income taxes					(78)	(205)	(268)	(118)		(669)
Net Income					$ (78)	$ (205)	$ (268)	$ (118)		$ (669)
Net income per share
Basic (in dollars per share)					$ 0	$ 0	$ (0.01)	$ 0		$ (0.02)
Diluted (in dollars per share)					$ (0.01)	$ 0	$ (0.01)	$ 0		$ (0.02)

Correction of Prior Period Im_6

Correction of Prior Period Immaterial Errors (Statements Cash Flow) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net Income	$ 2,388	$ 2,853	$ 1,326	$ 1,958	$ 2,968	$ 2,219	$ 2,098	$ 2,223	$ 8,525	$ 9,508
Increase in deferred revenue									725	807
Increase in prepaid expenses and other current assets									$ (623)	(473)
Previously Reported
Cash flows from operating activities
Net Income		$ 2,960	$ 1,820	$ 2,154	3,046	2,424	2,366	2,341		10,177
Increase in deferred revenue										0
Increase in prepaid expenses and other current assets										(335)
Corrections
Cash flows from operating activities
Net Income					$ (78)	$ (205)	$ (268)	$ (118)		(669)
Increase in deferred revenue										807
Increase in prepaid expenses and other current assets										$ (138)

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details) ft² in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	May 31, 2019ft²
Property, Plant and Equipment [Line Items]
Depreciation	$ 5,729	$ 3,195
Accumulated depreciation	13,680	8,822
Building
Property, Plant and Equipment [Line Items]
Property and equipment, gross	6,351	264
Capital lease
Property, Plant and Equipment [Line Items]
Property and equipment, gross	15,680	7,943
Capital lease
Property, Plant and Equipment [Line Items]
Accumulated depreciation	1,337	1,100
Medical equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	56,202	35,541
Accounts payable	$ 2,817	$ 4,785
Lafayette, Louisiana | Building
Property, Plant and Equipment [Line Items]
Area of commercial building (in square feet) | ft²			77

Property and Equipment (Schedul

Property and Equipment (Schedule of Fixed Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Property, Plant and Equipment [Line Items]
Less: Accumulated depreciation	$ (13,680)				$ (8,822)
Property and equipment, net of accumulated depreciation	54,772	$ 52,161	$ 45,803	$ 34,970	30,562	$ 27,248	$ 25,334	$ 22,726
Medical equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	56,202				35,541
Furniture and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,350				1,174
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,138				367
Building
Property, Plant and Equipment [Line Items]
Property and equipment, gross	6,351				264
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	301				256
Vehicles
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,110				$ 1,782

Current Liabilities (Details)

Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Payables and Accruals [Abstract]
Accrued trade payables	$ 1,023				$ 960
Accrued commissions payable	371				315
Accrued bonuses payable	2,292				3,788
Accrued vacation and payroll	1,502				1,012
Current portion of phantom share liability	3,129				1,476
Accrued other liabilities	651				0
Total accrued liabilities	$ 8,968	$ 8,600	$ 6,950	$ 5,850	$ 7,551	$ 5,741	$ 4,552	$ 4,246

Debt and lease liabilities (Sen

Debt and lease liabilities (Senior Credit Facility) (Details)	Feb. 20, 2018USD ($)	Dec. 31, 2019USD ($)	Sep. 19, 2019	Mar. 19, 2019USD ($)	Dec. 31, 2018USD ($)
Notes Payable | Term Note
Line of Credit Facility [Line Items]
Total Debt to Adjusted EBITDA (Quarterly)		1.03	1.50
Fixed Charge Coverage Ratio (Quarterly)		4.41	1.35
Loan-to-Value Ratio (Quarterly)		0.72	0.85
Line of Credit
Line of Credit Facility [Line Items]
Debt term	2 years
Floor rate	4.00%
Maximum borrowing capacity	$ 5,000,000			$ 10,000,000
Borrowings against facility		$ 0			$ 0
Line of Credit | ICE LIBOR
Line of Credit Facility [Line Items]
Basis spread on variable rate	3.00%

Debt and lease liabilities (Com

Debt and lease liabilities (Commercial Term Notes Narrative) (Details) - Notes Payable - USD ($)	Oct. 19, 2019	May 30, 2019	Sep. 19, 2019
Building Term Note
Debt Instrument [Line Items]
Principal amount		$ 4,845,000
Required loan to value ratio		85.00%
Building Term Note | Interest Rate
Debt Instrument [Line Items]
Fixed interest rate		4.68%
Building Term Note | ICE LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate		2.45%
Term Note
Debt Instrument [Line Items]
Principal amount			$ 5,000,000
Monthly principal payments	$ 139,000
Stated interest rate			4.60%

Debt and lease liabilities (Sch

Debt and lease liabilities (Schedule of Notes Payable) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Current portion of notes payable	$ (1,750)	$ (1,728)	$ (133)	$ 0	$ 0	$ 0	$ 0	$ 0
Net long-term notes payable	7,629	$ 8,076	$ 4,703	$ 0	0	$ 0	$ 0	$ 0
Notes Payable
Debt Instrument [Line Items]
Notes payable	9,379				0
Current portion of notes payable	(1,750)				0
Net long-term notes payable	$ 7,629				$ 0

Debt and lease liabilities (Fut

Debt and lease liabilities (Future Minimum Principal Obligations and Interest) (Details) - Notes Payable - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Principal Payments
2020	$ 1,750
2021	1,837
2022	1,475
2023	167
2024	176
Thereafter	3,974
Notes payable	9,379	$ 0
Interest Payments
2020	400
2021	319
2022	235
2023	201
2024	194
Thereafter	273
Total	$ 1,622
Building Term Note
Interest Payments
Effective percentage	4.68%
Term Note
Interest Payments
Effective percentage	4.60%

Debt and lease liabilities (Lea

Debt and lease liabilities (Lease Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Debt And Leases [Abstract]
Lease liabilities	$ 10,132				$ 3,425
Current portion of lease liabilities	(7,093)	$ (8,767)	$ (8,410)	$ (5,966)	(3,031)	$ (4,646)	$ (4,947)	$ (5,247)
Net long-term lease liabilities	$ 3,039	$ 2,813	$ 1,098	$ 1,188	$ 394	$ 719	$ 1,048	$ 1,307

Debt and lease liabilities (Fin

Debt and lease liabilities (Finance Lease Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Interest rate	10.98%
Weighted average interest rate	2.48%	1.78%
Weighted average lease term	1 year 25 days	10 months 17 days
Minimum payments and interest for finance lease obligations:
Interest expense	$ 147	$ 181
Principal Payments
Minimum payments and interest for finance lease obligations:
2020	6,538
2021	1,804
2022	11
Total	8,353
Interest Payments
Minimum payments and interest for finance lease obligations:
2020	155
2021	35
2022	0
Total	$ 190

Debt and lease liabilities (Ope

Debt and lease liabilities (Operating Lease Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Operating rental expenses	$ 408
Operating rental expenses		$ 404
Discount rate	5.50%
Weighted average lease term	4 years 17 days
Monthly Rental Payments | Related Party
Lessee, Lease, Description [Line Items]
Term of lease agreement	10 years
Minimum payments and interest for operating lease liabilities:
Rental payments	$ 20
Total rental payments	242	$ 235
Principal Payments
Minimum payments and interest for operating lease liabilities:
2020	555
2021	472
2022	212
2023	224
2024	227
Thereafter	89
Total	1,779
Interest Payments
Minimum payments and interest for operating lease liabilities:
2020	72
2021	51
2022	36
2023	24
2024	12
Thereafter	1
Total	$ 196

Fair value measurement (Narrati

Fair value measurement (Narrative) (Details)	12 Months Ended
	Dec. 31, 2019USD ($)swap$ / sharesshares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2019$ / shares	Dec. 31, 2017$ / shares	Dec. 21, 2017shares
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Number of shares called by each warrant (in shares)					0.10
Exercise of warrants (in shares)	133,000
Exercised (CAD per share) | $ / shares	$ 2.60	$ 2.60
Exercise price (CAD per share) | $ / shares		$ 2.60	$ 0	$ 9.74
Expired warrants (in shares)	44,000	2,422,000
Interest Rate
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Number of interest rate swaps | swap	1
Notional amount | $	$ 4,800,000
Fair value | $	$ 200,000

Fair value measurement (Warrant

Fair value measurement (Warrant Conversion Liability) (Details) - USD ($)	3 Months Ended							12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Warrant Conversion Liability
Unrealized (gain) loss on warrant conversion liability	$ (800,000)	$ 268,000	$ 169,000	$ (210,000)	$ 220,000	$ 123,000	$ 72,000	$ (363,000)	$ 205,000
Warrant
Warrant Conversion Liability
Beginning balance			$ 363,000				$ 158,000	363,000	158,000
Warrants issued								0	0
Loss on warrant conversion liability									205,000
Unrealized (gain) loss on warrant conversion liability								(363,000)
Ending balance				$ 363,000				$ 0	$ 363,000

Shareholders' Equity (Issued an

Shareholders' Equity (Issued and Outstanding Share Capital) (Details) - USD ($) $ in Thousands	7 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Nov. 29, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Shares outstanding (in shares)		37,952,660	37,500,815
Shares issued (in shares)		37,952,660	37,500,815
Shares repurchased and canceled under the Normal Course Issuer Bid		$ 1,522	$ 1,594
NCIB
Class of Stock [Line Items]
Number of shares authorized to be repurchased (in shares)				1,875,575
Percentage of shares issued and outstanding				5.00%
Shares repurchased and canceled under the Normal Course Issuer Bid (in shares)		365,100
Shares repurchased and canceled under the Normal Course Issuer Bid		$ 1,522
Shares repurchased under the Normal Course Issuer Bid (in shares)	775,803
Common Stock
Class of Stock [Line Items]
Shares outstanding (in shares)		37,952,660	37,500,815		37,909,628
Shares issued (in shares)		37,952,660	37,500,815
Shares repurchased and canceled under the Normal Course Issuer Bid (in shares)		365,100	410,703

Shareholders' Equity (Warrants)

Shareholders' Equity (Warrants) (Details)	12 Months Ended
	Dec. 31, 2019USD ($)shares	Dec. 31, 2019$ / shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2018$ / shares
Number of warrants (000's)
Beginning balance (in shares)	177,000		2,601,000
Exercised (in shares)	(133,000)		(2,000)
Issued (in shares)	0
Expired (in shares)	(44,000)		(2,422,000)
Ending balance (in shares)	0		177,000
Weighted average exercise price (CAD$)
Beginning balance (CAD per share) | $ / shares		$ 2.60		$ 9.74
Exercised (CAD per share) | $ / shares		2.60		2.60
Expired (CAD per share) | $ / shares		2.60		10.27
Issued (CAD per share) | $ / shares		0
Ending balance (CAD per share) | $ / shares		$ 0		$ 2.60
Exercise of warrants (in shares)	133,000
Warrant
Weighted average exercise price (CAD$)
Warrants issued | $	$ 0		$ 0

Shareholders' Equity (Stock-bas

Shareholders' Equity (Stock-based Compensation) (Details) - USD ($) $ in Thousands	3 Months Ended							12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Maximum shares in Plan (in shares)								7,582,000
Percent of issued and outstanding shares								20.00%
Options outstanding (in shares)				1,545,000				2,683,234	1,545,000	878,000
Stock-based compensation, expense	$ 1,064	$ 1,034	$ 880	$ 804	$ 672	$ 665	$ 561	$ 3,886	$ 2,702
Unrecognized pre-tax stock option expense								$ 1,947
Weighted-average period of recognition								2 years 17 days
Options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense								$ 2,642	$ 802
Restricted Stock Units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
RSUs outstanding (in shares)				1,715,000				1,139,310	1,715,000	0
Stock-based compensation, expense								$ 1,244	$ 1,900
Unrecognized pre-tax compensation expense, restricted stock units								$ 657
Weighted-average period of recognition								6 months 18 days

Shareholders' Equity (Options,

Shareholders' Equity (Options, Stock Option Activity) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares
Number of options (000's)
Beginning balance (in shares) | shares	1,545,000	878,000
Issued (in shares) | shares	1,269,000	696,000
Exercised (in shares) | shares	(42,000)
Expired / Forfeited (in shares) | shares	(89,000)	(29,000)
Ending balance (in shares) | shares	2,683,234	1,545,000	878,000
Weighted average exercise price (CAD$)
Beginning balance (CAD per share) | $ / shares	$ 3.39	$ 4.31
Issued (CAD per share) | $ / shares	5.77	2.27
Exercised (CAD per share) | $ / shares	4.30
Expired / Forfeited (CAD per share) | $ / shares	7.54	4.43
Ending balance (CAD per share) | $ / shares	$ 4.36	$ 3.39	$ 4.31
Weighted average remaining contractual life
Weighted average remaining contractual life	6 years 7 months 25 days	5 years 9 months 18 days	2 years 4 months 1 day
Aggregate Intrinsic Value
Aggregate Intrinsic Value | $	$ 7,790	$ 1,605	$ 65

Shareholders' Equity (Options_2

Shareholders' Equity (Options, Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2019$ / shares	Dec. 31, 2018$ / shares	Dec. 31, 2017USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value, outstanding | $	$ 7,790	$ 1,605			$ 65
Aggregate intrinsic value, exercisable | $	$ 3,431
Common stock issued pursuant to stock options (in shares)	42,000
Exercisable (in shares)	1,037,000	851,000
Weighted average exercise price (CAD per share) | $ / shares			$ 3.83	$ 4.30
Weighted average remaining contractual term	3 years 5 months 15 days	3 years 2 months 12 days
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued pursuant to stock options (in shares)	42,168

Shareholders' Equity (Options_3

Shareholders' Equity (Options, Fair Value Assumptions) (Details) - Options	12 Months Ended
	Dec. 31, 2019$ / shares	Dec. 31, 2018$ / shares	Dec. 31, 2019$ / shares	Dec. 31, 2018$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (CAD per share)				$ 2.18
Risk-free interest rate, minimum	1.59%
Risk-free interest rate, maximum	1.96%	2.27%
Expected volatility, minimum	73.00%
Expected volatility, maximum	81.00%	138.14%
Expected life of options	10 years	10 years
Fair value on date of grant		$ 2.27
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (CAD per share)			$ 5.49
Fair value on date of grant	$ 3.40
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (CAD per share)			$ 9.26
Fair value on date of grant	$ 5.52

Shareholders' Equity (Restricte

Shareholders' Equity (Restricted Stock Units) (Details) - Restricted Stock Units $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares
Number of Restricted Stock Units (000's)
Beginning balance (in shares) | shares	1,715,000	1,715,000	0
Issued (in shares) | shares	120,444	120,444	1,774,347
Vested (in shares) | shares	(641,000)	(641,000)
Expired / Forfeited (in shares) | shares	(55,134)	(55,134)	(59,000)
Ending balance (in shares) | shares	1,139,310	1,139,310	1,715,000	0
Weighted average grant price (CAD$)
Beginning balance (CAD per share)		$ 2.41	$ 0
Issued (CAD per share)		6.90	2.41
Vested (CAD per share)		2.68
Expired / Forfeited (CAD per share)		2.25	2.25
Ending balance (CAD per share)		$ 2.74	$ 2.41	$ 0
Weighted average remaining contractual life
Weighted average remaining contractual life	6 months 18 days	6 months 18 days	1 year 3 days	0 years
Aggregate Intrinsic Value
Aggregate Intrinsic Value | $	$ 7,129	$ 7,129	$ 6,575	$ 0
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year	1 year
Weighted average grant price (CAD$)
Issued (CAD per share)	$ 1.71
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years	3 years
Weighted average grant price (CAD$)
Issued (CAD per share)	$ 6.14

Shareholders' Equity (Phantom S

Shareholders' Equity (Phantom Share Units) (Details) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2019$ / shares	Dec. 31, 2018$ / shares
Fair Value Assumptions
Current accrued liabilities | $	$ 3,129	$ 1,476
Phantom Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Number of Phantom Share Units (000's)
Beginning balance (in shares) | shares	1,692	0
Issued (in shares) | shares	351	1,793
Vested (in shares) | shares	(550)
Expired / Forfeited (in shares) | shares	(143)	(101)
Ending balance (in shares) | shares	1,350	1,692
Fair Value Assumptions
Share price (USD per share) | $ / shares			$ 8.13	$ 5.23
Calculated fair value of phantom share units | $	$ 5,290	$ 2,593
Total liability | $	5,290
Long-term accrued liabilities | $	2,161
Current accrued liabilities | $	$ 3,129
Phantom Share Units | Minimum
Fair Value Assumptions
Remaining life of phantom share units	4 months 9 days	6 months
Phantom Share Units | Maximum
Fair Value Assumptions
Remaining life of phantom share units	2 years 4 months 9 days	3 years

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Compensation Related Costs [Abstract]
Matching employer contributions	$ 615	$ 440

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Effective tax rate	3.08%	1.67%

Income Taxes (Effective Income

Income Taxes (Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	3 Months Ended							12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Net income before income taxes	$ 2,904	$ 1,350	$ 2,096	$ 3,095	$ 2,254	$ 2,098	$ 2,223	$ 8,796	$ 9,670
Statutory income tax rate								21.00%	21.00%
Computed provision for income taxes								$ 1,847	$ 2,031
State income tax expense								632	473
Permanent differences								264	327
Deferred balance adjustments								(922)	43
Tax rate changes								0	(1,161)
Changes in valuation allowance for deferred tax assets								(1,550)	(1,551)
Provision for income taxes	$ 51	$ 24	$ 138	$ 127	$ 35	$ 0	$ 0	$ 271	$ 162

Income Taxes (Provision for Inc

Income Taxes (Provision for Income Taxes) (Details) - USD ($) $ in Thousands	3 Months Ended							12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Current taxes:
Federal								$ 0	$ 0
State								271	162
Foreign								0	0
Total current taxes								271	162
Deferred taxes								0	0
Provision for income taxes	$ 51	$ 24	$ 138	$ 127	$ 35	$ 0	$ 0	$ 271	$ 162

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating losses - US	$ 2,460	$ 980
Non-capital losses - CAD	0	3
Goodwill	13,149	14,403
Allowance for doubtful accounts	2,016	1,105
Accrued compensation and other	595	37
Accrued phantom stock	1,370	672
Stock-based compensation	1,516	914
Deferred Revenue	858	638
Lease Liability	460
Charitable Contributions	12	0
Other	40	0
UNICAP	5	19
481(a) adjustment	0	10
Total deferred tax assets	22,481	18,781
Deferred tax liabilities:
Right-Of-Use Asset	(460)	0
Property and equipment	(10,949)	(6,196)
Total deferred tax liabilities	11,409	6,196
Valuation allowance:
Net deferred tax asset before valuation allowance	11,072	12,585
Less: valuation allowance	(11,072)	(12,585)
Net deferred tax asset	$ 0	$ 0
Amortization period	15 years

Income Taxes (Loss Carryforward

Income Taxes (Loss Carryforwards) (Details) - US $ in Thousands	Dec. 31, 2019USD ($)
Operating Loss Carryforwards [Line Items]
Loss carryforwards, no expiration	$ 7,319
Expiring in 2034
Operating Loss Carryforwards [Line Items]
Loss carryforwards	2,027
Expiring in 2037
Operating Loss Carryforwards [Line Items]
Loss carryforwards	$ 153

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Net income attributable to shareholders	$ 2,388	$ 2,853	$ 1,326	$ 1,958	$ 2,968	$ 2,219	$ 2,098	$ 2,223	$ 8,525	$ 9,508
Denominator:
Basic weighted-average number of common shares (in shares)									37,716,864	37,892,118
Diluted weighted-average number of shares (in shares)									39,747,509	39,677,704
Basic earnings per share (in dollars per share)	$ 0.06	$ 0.08	$ 0.04	$ 0.05	$ 0.08	$ 0.06	$ 0.05	$ 0.06	$ 0.23	$ 0.25
Diluted earnings per share (in dollars per share)	$ 0.06	$ 0.07	$ 0.03	$ 0.05	$ 0.07	$ 0.06	$ 0.05	$ 0.06	$ 0.21	$ 0.24
Denominator calculation from basic to diluted:
Basic weighted-average number of common shares (in shares)									37,716,864	37,892,118
Stock options and other dilutive securities (in shares)									2,030,645	1,785,586
Diluted weighted-average number of shares (in shares)									39,747,509	39,677,704

Subsequent Events (Details)

Subsequent Events (Details) $ in Thousands	2 Months Ended
	Mar. 03, 2020USD ($)
Subsequent Event
Subsequent Event [Line Items]
Conversion of accounts payable into short-term capital lease	$ 1,816

Unaudited Summarized Quarterl_3

Unaudited Summarized Quarterly Financial Information (Quarterly Results) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 21,448	$ 20,368	$ 20,325	$ 18,115	$ 18,363	$ 16,930	$ 15,208	$ 13,963	$ 80,256	$ 64,464
Gross profit	14,243	14,050	14,639	13,074	13,519	12,829	11,023	10,404	56,006	47,775
Income from operations	2,658	2,160	1,638	2,291	2,915	2,511	2,288	2,342	8,747	10,056
Net Income	$ 2,388	$ 2,853	$ 1,326	$ 1,958	$ 2,968	$ 2,219	$ 2,098	$ 2,223	$ 8,525	$ 9,508
Net income per share
Basic (in dollars per share)	$ 0.06	$ 0.08	$ 0.04	$ 0.05	$ 0.08	$ 0.06	$ 0.05	$ 0.06	$ 0.23	$ 0.25
Diluted (in dollars per share)	$ 0.06	$ 0.07	$ 0.03	$ 0.05	$ 0.07	$ 0.06	$ 0.05	$ 0.06	$ 0.21	$ 0.24

Unaudited Summarized Quarterl_4

Unaudited Summarized Quarterly Financial Information (Adjustments To Quarterly Results, Income Statement) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Effect of Fourth Quarter Events [Line Items]
Revenue	$ 21,448	$ 20,368	$ 20,325	$ 18,115	$ 18,363	$ 16,930	$ 15,208	$ 13,963	$ 80,256	$ 64,464
Cost of revenue		6,318	5,686	5,041	4,844	4,101	4,185	3,559	24,250	16,689
Gross profit	14,243	14,050	14,639	13,074	13,519	12,829	11,023	10,404	56,006	47,775
Operating Expenses
Selling, general and administrative		10,231	11,516	9,460	9,696	9,462	7,887	7,259	41,381	34,304
Research and development		208	203	234	0	0	0	0	848	0
Stock-based compensation		1,064	1,034	880	804	672	665	561	3,886	2,702
Depreciation		193	138	129	130	128	124	206	671	588
Loss on disposal of property and equipment		167	85	56	(57)	23	52	36	360	54
Other expense		27	25	24	31	33	7	0	113	71
Income from operations	2,658	2,160	1,638	2,291	2,915	2,511	2,288	2,342	8,747	10,056
Non-operating expenses
Unrealized (gain) loss on warrant conversion liability		(800)	268	169	(210)	220	123	72	(363)	205
Interest expense, net of interest income		56	20	26	30	37	67	47	314	181
Net income before taxes		2,904	1,350	2,096	3,095	2,254	2,098	2,223	8,796	9,670
Provision for income taxes		51	24	138	127	35	0	0	271	162
Net income	$ 2,388	$ 2,853	$ 1,326	$ 1,958	$ 2,968	$ 2,219	$ 2,098	$ 2,223	$ 8,525	$ 9,508
Net income per share
Basic (in dollars per share)	$ 0.06	$ 0.08	$ 0.04	$ 0.05	$ 0.08	$ 0.06	$ 0.05	$ 0.06	$ 0.23	$ 0.25
Diluted (in dollars per share)	$ 0.06	$ 0.07	$ 0.03	$ 0.05	$ 0.07	$ 0.06	$ 0.05	$ 0.06	$ 0.21	$ 0.24
Previously Reported
Effect of Fourth Quarter Events [Line Items]
Revenue		$ 23,525	$ 22,547	$ 20,443	$ 18,489	$ 17,163	$ 15,508	$ 14,111		$ 65,271
Cost of revenue		6,318	5,686	5,041	4,844	4,101	4,185	3,559
Gross profit		17,207	16,861	15,402	13,645	13,062	11,323	10,552		48,582
Operating Expenses
Selling, general and administrative		13,281	13,244	11,592	9,744	9,490	7,919	7,289		34,442
Research and development		208	203	234	0	0	0	0
Stock-based compensation		1,064	1,034	880	804	672	665	561
Depreciation		193	138	129	130	128	124	206
Loss on disposal of property and equipment		167	85	56	(57)	23	52	36
Other expense		27	25	24	31	33	7	0
Income from operations		2,267	2,132	2,487	2,993	2,716	2,556	2,460		10,725
Non-operating expenses
Unrealized (gain) loss on warrant conversion liability		(800)	268	169	(210)	220	123	72
Interest expense, net of interest income		56	20	26	30	37	67	47
Net income before taxes		3,011	1,844	2,292	3,173	2,459	2,366	2,341		10,339
Provision for income taxes		51	24	138	127	35	0	0
Net income		$ 2,960	$ 1,820	$ 2,154	$ 3,046	$ 2,424	$ 2,366	$ 2,341		$ 10,177
Net income per share
Basic (in dollars per share)		$ 0.08	$ 0.05	$ 0.06	$ 0.08	$ 0.06	$ 0.06	$ 0.06		$ 0.27
Diluted (in dollars per share)		$ 0.07	$ 0.05	$ 0.05	$ 0.08	$ 0.06	$ 0.06	$ 0.06		$ 0.26
Corrections
Effect of Fourth Quarter Events [Line Items]
Revenue					$ (126)	$ (233)	$ (300)	$ (148)		$ (807)
Cost of revenue					0	0	0	0
Gross profit					(126)	(233)	(300)	(148)		(807)
Operating Expenses
Selling, general and administrative					(48)	(28)	(32)	(30)		(138)
Research and development					0	0	0	0
Stock-based compensation					0	0	0	0
Depreciation					0	0	0	0
Loss on disposal of property and equipment					0	0	0	0
Other expense					0	0	0	0
Income from operations					(78)	(205)	(268)	(118)		(669)
Non-operating expenses
Unrealized (gain) loss on warrant conversion liability					0	0	0	0
Interest expense, net of interest income					0	0	0	0
Net income before taxes					(78)	(205)	(268)	(118)		(669)
Provision for income taxes					0	0	0	0
Net income					$ (78)	$ (205)	$ (268)	$ (118)		$ (669)
Net income per share
Basic (in dollars per share)					$ 0	$ 0	$ (0.01)	$ 0		$ (0.02)
Diluted (in dollars per share)					$ (0.01)	$ 0	$ (0.01)	$ 0		$ (0.02)
Corrections | Bad Debt Presentation
Effect of Fourth Quarter Events [Line Items]
Revenue		$ (3,078)	$ (1,733)	$ (2,125)
Cost of revenue		0	0	0
Gross profit		(3,078)	(1,733)	(2,125)
Operating Expenses
Selling, general and administrative		(3,078)	(1,733)	(2,125)
Research and development		0	0	0
Stock-based compensation		0	0	0
Depreciation		0	0	0
Loss on disposal of property and equipment		0	0	0
Other expense		0	0	0
Income from operations		0	0	0
Non-operating expenses
Unrealized (gain) loss on warrant conversion liability		0	0	0
Interest expense, net of interest income		0	0	0
Net income before taxes		0	0	0
Provision for income taxes		0	0	0
Net income		$ 0	$ 0	$ 0
Net income per share
Basic (in dollars per share)		$ 0	$ 0	$ 0
Diluted (in dollars per share)		$ 0	$ 0	$ 0
Corrections | Corrections
Effect of Fourth Quarter Events [Line Items]
Revenue		$ (79)	$ (489)	$ (203)
Cost of revenue		0	0	0
Gross profit		(79)	(489)	(203)
Operating Expenses
Selling, general and administrative		28	5	(7)
Research and development		0	0	0
Stock-based compensation		0	0	0
Depreciation		0	0	0
Loss on disposal of property and equipment		0	0	0
Other expense		0	0	0
Income from operations		(107)	(494)	(196)
Non-operating expenses
Unrealized (gain) loss on warrant conversion liability		0	0	0
Interest expense, net of interest income		0	0	0
Net income before taxes		(107)	(494)	(196)
Provision for income taxes		0	0	0
Net income		$ (107)	$ (494)	$ (196)
Net income per share
Basic (in dollars per share)		$ 0	$ (0.01)	$ (0.01)
Diluted (in dollars per share)		$ 0	$ (0.02)	$ 0

Unaudited Summarized Quarterl_5

Unaudited Summarized Quarterly Financial Information (Adjustments To Quarterly Results, Balance Sheet) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 13,355	$ 12,630	$ 7,691	$ 7,410	$ 10,413	$ 10,174	$ 8,551	$ 4,634
Accounts receivable, net of allowance for doubtful accounts of $7,782 and $4,266 at December 31, 2019 and December 31, 2018, respectively	11,534	11,729	12,797	11,666	8,839	8,392	7,857	10,687
Inventory, net	1,360	1,266	3,712	3,615	2,887	2,377	1,935	1,959
Prepaid expenses and other assets	1,562	2,178	989	1,057	952	1,049	579	650
Total current assets	27,811	27,803	25,189	23,748	23,091	21,992	18,922	17,930
Long-term assets
Property and equipment	54,772	52,161	45,803	34,970	30,562	27,248	25,334	22,726
Other assets	13	17	22	0	0	0	0	0
Total long-term assets	54,785	52,178	45,825	34,970	30,562	27,248	25,334	22,726
TOTAL ASSETS	82,596	79,981	71,014	58,718	53,653	49,240	44,256	40,656
Current liabilities
Trade payables	4,700	4,072	7,818	6,388	5,884	3,683	3,266	2,780
Deferred revenue	3,315	3,360	3,281	2,793	2,590	2,477	2,267	1,997
Income taxes payable	86	28	0	148	152	74	73	110
Accrued liabilities	8,968	8,600	6,950	5,850	7,551	5,741	4,552	4,246
Current portion of lease liabilities	7,093	8,767	8,410	5,966	3,031	4,646	4,947	5,247
Current portion of long-term debt	1,750	1,728	133	0	0	0	0	0
Warrant conversion liability	0	0	800	532	363	572	353	230
Total current liabilities	25,912	26,555	27,392	21,677	19,571	17,193	15,458	14,610
Long-term liabilities
Accrued liabilities	2,317	2,213	1,685	1,962	1,117	936	252	0
Long-term lease liabilities	3,039	2,813	1,098	1,188	394	719	1,048	1,307
Long-term debt	7,629	8,076	4,703	0	0	0	0	0
Total long-term liabilities	12,985	13,102	7,486	3,150	1,511	1,655	1,300	1,307
TOTAL LIABILITIES	38,897	39,657	34,878	24,827	21,082	18,848	16,758	15,917
SHAREHOLDERS' EQUITY
Common stock	3,366	3,366	2,350	2,277	71	70	67	67
Additional paid-in capital	6,377	5,470	5,063	4,068	5,390	4,586	3,914	3,249
Accumulated other comprehensive loss	(157)	(236)	(148)	0	0	0	0	0
Retained earnings	34,113	31,724	28,871	27,546	27,110	25,736	23,517	21,423
TOTAL SHAREHOLDERS' EQUITY	43,699	40,324	36,136	33,891	32,571	30,392	27,498	24,739	$ 21,951
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 82,596	79,981	71,014	58,718	53,653	49,240	44,256	40,656
Previously Reported
Current assets
Cash and cash equivalents		12,630	7,691	7,410	10,413	10,174	8,551	4,634
Accounts receivable, net of allowance for doubtful accounts of $7,782 and $4,266 at December 31, 2019 and December 31, 2018, respectively		11,729	12,797	11,666	8,839	8,392	7,857	10,687
Inventory, net		1,266	3,712	3,615	2,887	2,377	1,935	1,959
Prepaid expenses and other assets		2,078	861	922	824	956	491	560
Total current assets		27,703	25,061	23,613	22,963	21,899	18,834	17,840
Long-term assets
Property and equipment		52,161	45,803	34,970	30,562	27,248	25,334	22,726
Other assets		17	22	0	0	0	0	0
Total long-term assets		52,178	45,825	34,970	30,562	27,248	25,334	22,726
TOTAL ASSETS		79,881	70,886	58,583	53,525	49,147	44,168	40,566
Current liabilities
Trade payables		4,072	7,818	6,388	5,884	3,683	3,266	2,780
Deferred revenue		0	0	0	0	0	0	0
Income taxes payable		28	0	148	152	74	73	110
Accrued liabilities		8,600	6,950	5,850	7,551	5,741	4,552	4,246
Current portion of lease liabilities		8,767	8,410	5,966	3,031	4,646	4,947	5,247
Current portion of long-term debt		1,728	133	0	0	0	0	0
Warrant conversion liability		0	800	532	363	572	353	230
Total current liabilities		23,195	24,111	18,884	16,981	14,716	13,191	12,613
Long-term liabilities
Accrued liabilities		2,213	1,685	1,962	1,117	936	252	0
Long-term lease liabilities		2,813	1,098	1,188	394	719	1,048	1,307
Long-term debt		8,076	4,703	0	0	0	0	0
Total long-term liabilities		13,102	7,486	3,150	1,511	1,655	1,300	1,307
TOTAL LIABILITIES		36,297	31,597	22,034	18,492	16,371	14,491	13,920
SHAREHOLDERS' EQUITY
Common stock		3,366	2,350	2,277	71	70	67	67
Additional paid-in capital		5,470	5,063	4,068	5,390	4,586	3,914	3,249
Accumulated other comprehensive loss		(236)	(148)	0	0	0	0	0
Retained earnings		34,984	32,024	30,204	29,572	28,120	25,696	23,330
TOTAL SHAREHOLDERS' EQUITY		43,584	39,289	36,549	35,033	32,776	29,677	26,646
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		79,881	70,886	58,583	53,525	49,147	44,168	40,566
Corrections
Current assets
Cash and cash equivalents		0	0	0	0	0	0	0
Accounts receivable, net of allowance for doubtful accounts of $7,782 and $4,266 at December 31, 2019 and December 31, 2018, respectively		0	0	0	0	0	0	0
Inventory, net		0	0	0	0	0	0	0
Prepaid expenses and other assets		100	128	135	128	93	88	90
Total current assets		100	128	135	128	93	88	90
Long-term assets
Property and equipment		0	0	0	0	0	0	0
Other assets		0	0	0	0	0	0	0
Total long-term assets		0	0	0	0	0	0	0
TOTAL ASSETS		100	128	135	128	93	88	90
Current liabilities
Trade payables		0	0	0	0	0	0	0
Deferred revenue		3,360	3,281	2,793	2,590	2,477	2,267	1,997
Income taxes payable		0	0	0	0	0	0	0
Accrued liabilities		0	0	0	0	0	0	0
Current portion of lease liabilities		0	0	0	0	0	0	0
Current portion of long-term debt		0	0	0	0	0	0	0
Warrant conversion liability		0	0	0	0	0	0	0
Total current liabilities		3,360	3,281	2,793	2,590	2,477	2,267	1,997
Long-term liabilities
Accrued liabilities		0	0	0	0	0	0	0
Long-term lease liabilities		0	0	0	0	0	0	0
Long-term debt		0	0	0	0	0	0	0
Total long-term liabilities		0	0	0	0	0	0	0
TOTAL LIABILITIES		3,360	3,281	2,793	2,590	2,477	2,267	1,997
SHAREHOLDERS' EQUITY
Common stock		0	0	0	0	0	0	0
Additional paid-in capital		0	0	0	0	0	0	0
Accumulated other comprehensive loss		0	0	0	0	0	0	0
Retained earnings		(3,260)	(3,153)	(2,658)	(2,462)	(2,384)	(2,179)	(1,907)	$ (1,800)
TOTAL SHAREHOLDERS' EQUITY		(3,260)	(3,153)	(2,658)	(2,462)	(2,384)	(2,179)	(1,907)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		$ 100	$ 128	$ 135	$ 128	$ 93	$ 88	$ 90